Herbal melanin modulates PGE2 and IL-6 gastroprotective markers through COX-2 and TLR4 signaling in the gastric cancer cell line AGS

Herbal melanin modulates PGE2 and IL-6 gastroprotective markers through COX-2 and TLR4 signaling in the gastric cancer cell line AGS | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Herbal melanin modulates PGE2 and IL-6 gastroprotective markers through COX-2 and TLR4 signaling in the gastric cancer cell line AGS Adila El-Obeid, Yahya Maashi, Ghada Alatar, Modhi Aljudayi, Hamad Al-Eidi, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-1597711/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 11 You are reading this latest preprint version Abstract We reported a gastric anti-ulcerogenic effect of the Nigella sativa (L.)-derived herbal melanin (HM) in rat models. However, the molecular mechanisms underlying the HM gastroprotective effect remain unknown. Cyclooxygenase-2 (COX-2)-catalyzed prostaglandin E2 (PGE2) and toll-like receptor 4 (TLR4)-mediated interleukin-6 (IL-6) production and secretion play major roles in gastric mucosal protection. In the current study, we investigated the effect of HM on TLR4, COX-2, and on gastroprotective markers PGE2 and IL-6 expression, using the human gastric cancer cell line AGS. Bacterial lipopolysaccharide (LPS), a well-known inducer of gastroprotective marker expression, was used as a positive control. After cell exposure to HM and LPS, the cell lysates and supernatants were tested for COX-2, PGE2, and IL-6 production and secretion using Western blot technology and an enzyme-linked immunosorbent assay (ELISA), respectively. Immuno-cyto-fluorescence staining was applied for COX-2 cellular localization and RT-qPCR for monitoring the gene expression levels of TLR4, COX-2, and mucin 4, an important gastroprotective glycoprotein. In this study, we showed that HM upregulated its main receptor TLR4 gene and protein expression. HM increased, in a dose- and time-dependent manner, the secretion of PGE2 and the expression of COX-2 mRNA and protein, which was detected in the nucleus, cytoplasm and predominantly at the intercellular junctions. In addition, HM enhanced IL-6 production and secretion, and upregulated the mucin 4 gene expression, the hallmarks of gastroprotection. To check whether HM-induced PGE2 and IL-6 through TLR4 signaling and COX-2 generated, AGS cells were pre-treated with a TLR4 signaling inhibitor TAK242 and the COX-2 inhibitor NS-398. An inhibition of HM-induced COX-2, PGE2 and IL-6 production was observed in TAK242 and NS-398-pre-treated AGS cells, confirming the role of TLR4 signaling and of COX-2 generated in the possible HM gastroprotective effects. In conclusion, our results showed that HM enhances TLR4/COX-2-mediated secretion of gastroprotective markers PGE2 and IL-6, and upregulates mucin 4 gene expression in the human gastric cancer cell line AGS. Herbal melanin gastrointestinal gastroprotection TLR COX-2 IL-6 Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Introduction The structural and functional integrity of the intestinal mucosa ( i.e ., epithelium lining the gastrointestinal (GI) tract) are naturally maintained by the balance between aggressive forces and protective mechanisms [1]. The intestinal mucosa layer provides a physical barrier and is the first line of immunological defense against invasion by bacteria, viruses and harmful endogenous macromolecules [1]. Multiple defense mechanisms protect the GI tract, including the mucus gel layer, intercellular tight junctions, mucosal nerves and toll-like receptors (TLRs) [1, 2]. Cyclooxygenase 2 (COX-2) and prostaglandin E2 (PGE2) play a crucial role in mucosal protection [3]. COX-2 and COX-1 proteins are both isoforms of cyclooxygenase (COX) that catalyze PGE2 biosynthesis from arachidonic acid, following its release from the plasma membrane via phospholipase A2 [4]. COX is expressed by the normal gastric mucosa. It contributes to the preservation of the mucosal integrity via PGE2 production [5]. Well known as a mediator of inflammation that regulates tissue regeneration, PGE2 is one of the most important biologically active prostanoids found throughout the GI tract for its physiological functions, including GI secretions and motility [3, 6]. The inhibition of COX-2 and PGE2 causes a decrease in mucus and bicarbonate secretion, reduces mucosal blood flow, and causes vascular injury resulting in mucosal damage [3, 7]. A growing body of experimental and clinical evidence suggests that gastric mucosal damage is mediated through the inhibition of COX-2 and PGE2 by nonsteroidal anti-inflammatory drugs (NSAIDs) [8]. The activation of the COX-2/PGE2 signaling pathway via TLRs has been reported in the GI tract [9, 10]. TLRs are members of a superfamily of transmembrane receptors that recognize pathogen-associated molecular patterns and are a subset of pathogen-recognition receptors. The expression of TLRs has been detected in the GI tract in the epithelial cells, lamina propria, dendritic and Paneth cells [11]. The TLRs expressed on the gastric mucosa are constantly exposed and activated by microbial ligands produced by pathogenic and commensal bacteria. It is acknowledged that the interaction between the gut microbiota and the local TLRs support the maintenance of homeostasis in the GI tract [12]. Various studies demonstrated the expression and activation of TLR4 by bacterial lipopolysaccharide (LPS) in the intestinal mucosa [13, 14]. In addition, the activation of the TLR4/COX-2 and of TLR4/NF-kB signaling pathways induce PGE2 and interleukin (IL)-6 production, respectively, resulting in gastric mucosal protection [15-17]. The IL-6 cytokine, originally identified as a B-cell–stimulating factor 2, is mainly known as an important induced inflammatory modulator, which exerts inhibitory and stimulatory effects on the innate and adaptive immune cells at certain levels of inflammation, in response to infection or tissue injury [17, 18]. IL-6 has pleiotropic activities, which contribute to gastric homeostasis through the regulation of metabolic and regenerative processes, including mucosal repairing [17]. In addition, IL-6 protects the mucosa against ulceration and upregulate mucin 4 expression in cultured gastric cancer cell lines [19, 20]. Numerous studies reported the effects of medicinal natural products, including Nigella sativa L. extracts, on antigen-presenting cells stimulating the release of key cytokines such as IL-6, suggesting a beneficial gastroprotective effect of the natural products for the prevention and the treatment of inflammatory diseases, including stomach ulcers [21-25]. Herbal melanin (HM) has been extracted from Nigella sativa L. (Black cumin), an annual herbaceous plant in the family Ranunculaceae that widely grows in the Mediterranean countries, Western Asia, Southern Europe, and Middle East [26]. This plant is considered as one of the greatest traditional healing herb and numerous research has been carried out on its medicinal properties [27], such as anticancer [28], antidiabetic [29], antimicrobial [30], hepatoprotective [31], anti-inflammatory and antioxidant [32] agent. HM has been presented as a macromolecule of a heterogeneous polymer mainly composed of 5,6-dihydroxyindole (DHI) and 5,6-dihydroxyindole-2-carboxylic acid (DHICA) [33, 34]. In addition, HM was demonstrated to act via TLRs (i.e., TLR4, its main receptor, and TLR2) leading to NF-kB and p38 MAPK activation, which result in interleukins ( i.e ., IL-8, IL-6, IL-1b) and vascular endothelial growth factor production by human monocytes [35-37]. High HM concentrations exert antiproliferative effects in human monocytic, embryonic kidney and colorectal cancer cell lines through induction of apoptosis [38, 39]. Various studies revealed beneficial effects of melanin on gastric health [40, 41]. We previously reported that HM acts as a strong anti-ulcerogenic agent against gastric ulcers induced in rats [24, 25], suggesting a protective action of HM in the gastrointestinal tract. However, the underlying molecular mechanisms contributing to the beneficial gastroprotective effects of HM remain elusive. In the current study, we investigated the gastroprotective effects of HM based on TLR4/COX2 expression, PGE2 and IL-6 secretion using the gastric cancer cell line AGS. Materials and Methods Reagents Herbal melanin (HM) was extracted from Nigella sativa L. seed coats that were purchased from a local public herbarium in Riyadh (Saudi Arabia). HM was prepared, analyzed and characterized as previously described in [33, 34]. HM was well solubilized in distilled water and the presence of endotoxins in the HM solution was below the detection level, using a fluorogenic endotoxin test (Lonza Verviers SPRL, Verviers, Belgium). Culture media and reagents were procured from Gibco® (Thermo Fisher Scientific Inc., Waltham, MA, USA). Lipopolysaccharides (LPS, purified from E. Coli ) and dimethyl sulfoxide (DMSO) were provided by Sigma-Aldrich Corp (St. Louis, MO). COX-2 specific NS-398 pharmacological inhibitor (#sc-200604) was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX). TLR4 signaling TAK242 pharmacological inhibitor (#6587/5) was procured from Tocris Bioscience™ (Bristol, UK). Cell culture and treatment The human gastric cancer cell line AGS (#CRL-1739™) was purchased from the American Type Culture Collection (Manassas, VA, USA). The AGS cells were cultured in complete medium composed of Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 1% antibiotics (100 mg/mL streptomycin, 100 IU/mL penicillin). The cells were cultured at 37°C in a humidified 5% CO2-incubator. Reaching 80-90% confluence, the cells were trypsinized and split in a ratio of 1:3 for each passage. Between passage 3 and 8, the cells were used for downstream applications. The cells were treated with either LPS tested at 10 mg/mL, dose reported to exhibit in vivo gastroprotective effects [42], or with various concentrations (5-10-20 mg/mL) of HM at different incubation time periods (4-24-48-72 h). Protein sample preparation and Western blot technology The AGS cells (5×10 5 cells) were seeded in complete medium in 12-well plates. The next day, the cells were incubated in the absence (the Control) or in the presence of either 10 mg/mL LPS or 5-10 and 20 µg/mL of HM, for different incubation time periods (24, 48, and 72 h). The cells were then trypsinized, washed and centrifuged at high-speed. The cell pellet was lysed using the NP40 lysis buffer (Invitrogen, Carlsbad, CA, USA) and the extracted protein samples were estimated using the Invitrogen Qubit™ Protein Assay kit according to the manufacturer’s instructions. The Western blot technology and analysis were done as described in [43] for the detection of COX-2, IL-6, TLR4, phospho-p65 NFkB, and total p65 NF-kB using goat anti-COX-2 antibody (#AF4198, R&D systems, Minneapolis, MN, USA), rabbit polyclonal anti-IL-6 antibody (#TA328217, OriGene Technologies Inc., Rockville, MD, USA), rabbit monoclonal anti-TLR4 antibody (#ab13867, Abcam, Cambridge, UK), rabbit monoclonal phospho-p65 (Ser 529) NF-kB (#44711G, Invitrogen, Thermo Fischer Scientific) and mouse monoclonal anti-p65 NF-kB (#sc-8008, Santa Cruz Biotechnology), respectively. Mouse monoclonal anti-GAPDH (#ab8245, Abcam) and rabbit monoclonal anti-a-Tubulin (#ab13867, Abcam) antibodies were used for the detection of the housekeeping proteins glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and a-Tubulin, used as loading controls. The Western blots were scanned and analyzed using an Odyssey CLx Scanner (LI-COR Biosciences, Lincoln, NE, USA) and ImageJ software (https://imagej.nih.gov/ij/download.html). Enzyme-Linked Immunosorbent Assay (ELISA) The AGS cells (1× 10 6 ) were seeded in complete medium in 12-well plate. The next day, the cells were incubated in the absence (the Control) or in the presence of either 10 mg/mL LPS or 5-10 and 20 µg/mL of HM, for different incubation time periods (4, 24, 48, and 72 h). The levels of PGE2 and IL-6 secreted in the supernatant were determined by ELISA. Human Prostaglandin E2 ELISA kit (#ADI-900-001, Enzo Life Sciences Inc., Farmingdale, NY, USA), R&D systems Prostaglandin E2 Assay Parameter ™ Assay kit (#KGE004B) and the human IL-6 Immunoassay Quantikine ELISA kit (#D6050, R&D systems) were used following the manufacturers’ instructions. The untreated cells, cultured in complete medium, were used as controls. Triplicate readings for each standard, control and sample were recorded as previously described in [33] and measured using a Molecular Devices SpectraMax® Plus 384 microplate reader. RNA extraction and RT-qPCR Total RNA extraction was carried out from the untreated and treated cells (1× 10 6 ) using the Qiagen RNeasy Mini Kit (Qiagen Inc., Fisher Scientific, Pittsburg, PA, USA) according to the manufacturer’s protocol. The RNA extract was reverse-transcribed to cDNA, and RT-qPCR was performed as previously described in [38]. The primer pair sequences (Invitrogen, Thermo Fisher Scientific) used were 5'-AGATCATCTCTGCCTGAGTATCTT-3' (forward) and 5'-TTCAAATGAGATTGTGGGAAAAT-3' (reverse) for human COX-2 gene; 5′-GAA GCT GGT GGC TGT GGA-3′ (forward) and 5′-TGA TGT AGA ACC CGC AAG-3′ (reverse) for human TLR4 gene. For the human MUC4 gene, the primer pair sequences (Macrogen Inc., Seoul, South Korea) used were 5'-GCTTACTTCAGATGCGATG-3' (forward) and 5'-GTCGAGTTTCATGCTCAGG-3' (reverse). The gene expression levels were monitored using an Applied Biosystems™ 7500 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA) and were detected, calculated and normalized to the expression of the housekeeping gene GAPDH , as described previously in [38]. Immunofluorescence staining The AGS cells (5×10 3 cells) were seeded on a Nunc® Lab-Tek™ II chambered cover glass. The next day, the cells were exposed to either 10 mg/mL HM or 10 mg/mL LPS at different incubation time periods (24, 48 and 72 h). After the incubation, the cells were rinsed with PBS, then fixed for 30 min at room temperature with 4% formaldehyde diluted in PBS, and the membrane permeabilization was done using 0.1 % Triton X-100 in PBS for 10 min, at room temperature. For COX-2 detection, the cells were mixed with either Santa Cruz Biotechnology fluorescein isothiocyanate (FITC)-conjugated mouse IgG1 (#sc-2855, used as a negative control, data not shown) or FITC-conjugated anti-human/mouse COX-2 antibody (#sc-19999). The immunofluorescence staining was captured using LSM780 confocal scanner lasing microscope (Carl Zeiss Microscopy GmbH, Jena, Germany). TLR4 signaling and COX-2 generation blockade To investigate whether HM acts through TLR4 signaling activation and COX-2 generation for the stimulation of IL-6 production/secretion and of PGE2 secretion, the AGS cells were treated with TAK242 and NS-398, used as specific pharmacological inhibitors of TLR4 signaling and COX-2, respectively. Briefly, the AGS cells (1× 10 6 ) were seeded in complete medium in a 12-well plate. The next day, the medium was renewed with 1 mM TAK242, 100 mM NS-398 (both were reconstituted in DMSO and concentration was fixed from optimization) and with 1% DMSO (corresponding to the highest pharmacological inhibitor concentration tested), used as a negative control. After 2 h incubation, the cells were exposed to either 10 mg/mL of HM or LPS for a further 72-h incubation, followed by supernatant collection for ELISA and protein extraction for Western blot technology. Statistical analysis All the data are expressed as mean ± standard deviation (SD) based on three independent experiments. A one-way ANOVA test was used for comparison of the two groups. The generalized estimating equations (GENMOD procedure) from SAS software was applied to compare the protein expression level between and within each treatment at the various exposure times. Each pairwise comparison was performed using a post-hoc Tukey test. Values of p < 0.05 were considered significant. Results HM upregulated TLR4 and COX-2 expression levels in the human gastric AGS cells TLR4 receptor is known as the main receptor for both LPS and HM, and COX-2 plays a key role in gastric mucosal protection [3, 35]. We monitored the protein and gene expression levels of TLR4 and COX-2 in the AGS cells after 72 h exposure to 5-10-20 mg/mL HM and 10 mg/mL LPS, using Western blot technology and RT-qPCR. A significant increase in the TLR4 protein expression was observed in the AGS cells treated with all HM concentrations (2.5-fold, p < 0.01) and with LPS (3.11-fold, p = 0.037), compared with the basal TLR4 expression level detected in untreated cells (Figure 1A). Monitored at 24 h and 72 h incubation, the HM-induced TLR4 expression was also confirmed at the gene expression level, compared to the untreated cells (Figure 1B). As depicted in Figure 2A, compared to the COX-2 basal expression level detected in the untreated AGS cells, the LPS significantly increased (2.25-fold, p = 0.015) the COX-2 expression level, and a dose-dependent effect of HM-induced COX-2 protein expression was observed reaching a peak of stimulation (4.47-fold, p = 0.0014) at 10 mg/mL of HM (Figure 2A). The COX-2 gene expression level was monitored in the untreated AGS cells and in the cells treated with either 10 mg/mL LPS or HM at different incubation time periods (24-48-72 h). Compared to the basal COX-2 expression levels detected in the untreated cells, a slight increase (1.2- and 1.5-fold, p < 0.05) in the COX-2 gene expression levels was induced by the LPS at 24 h and 48 h incubation and a concomitant enhancement (3.0-fold, p < 0.05) was observed after 72 h incubation of the cell treatment with LPS (Figure 3B). After 24 h incubation, HM did not change the COX-2 gene expression level, but a significant increase in the COX-2 gene expression level was observed after 48 h (3.2-fold, p < 0.01) and after 72 h (2.8-fold, p < 0.01) of incubation of the AGS cells treated with 10 mg/mL of HM, compared with untreated cells (Figure 2B). Using immunofluorescence staining, representative photomicrographs of the AGS cells incubated with the monoclonal antibody directed against COX-2 conjugated to FITC showed the diverse cellular localizations of COX-2 expressed after 24-48-72 h of cell treatment with 10 mg/mL of LPS or HM. The COX-2 localization was revealed to be in nuclear, cytoplasmic, plasma membrane compartments, and at the intercellular junctions (Figure 2C). After 72 h incubation, significant increases in intercellular junctions-bound COX-2 and cytoplasmic COX-2 expression levels were observed in the AGS cells treated with HM, to a higher extent than the LPS effect (Figure 2D). Slight significant enhancements of the plasma membrane-bound COX-2 and nuclear COX-2 expression levels were induced by LPS. However, the AGS cell treatment with HM resulted in a significant increase in the plasma membrane-bound COX-2 expression levels, as compared with the cellular localization of COX-2 expression levels determined in the untreated cells, the Control (Figure 2D). HM enhanced PGE2 secretion from the gastric AGS cells With COX-2 described to mediate PGE2 production, the AGS cell culture supernatants were collected after 4-24-48-72 h of treatment with 5-10-20 mg/mL of HM along with 10 mg/mL LPS. After 4 h incubation, a significant increase (1.8-fold, p = 0.0006) in secreted PGE2 concentration was observed after the AGS cell exposure to HM. The LPS did not change the secreted PGE2 production as compared with the basal level of the secreted PGE2 detected in untreated AGS cell culture supernatant collected at 4 h incubation (Figure 3). A gradual increase in the secreted PGE2 was observed over the incubation time of the AGS cell exposure to different HM concentrations, significant ( p < 0.0001) at 48 h incubation (2.56-fold increase at 10 mg/mL) and 72 h incubation (3.29-fold increase at 10 mg/mL), compared with the basal level of secreted PGE2 detected in untreated cells after 4 h incubation (Figure 3). A concomitant increase (3.96-fold, p < 0.0001) of secreted PGE2 was induced by the LPS after 72 h incubation, compared with the basal level of secreted PGE2 (Figure 4). Of note, no significant increase of the secreted PGE2 was revealed after the addition of HM (tested at all concentrations) and even after the cell treatment with LPS over 48 h incubation, as compared with the amount of secreted PGE2 released from untreated cells after 48 h incubation (Figure 3). However, after 72 h incubation, both the HM ( p = 0.0324) and the LPS ( p = 0.0005) tested at 10 mg/mL significantly enhanced the PGE2 secretion by the AGS cells, compared with the amount of secreted PGE2 released from the untreated cells after 72 h incubation (Figure 3). HM upregulated mucin 4 gene expression levels and induced PGE2 and IL-6 production and secretion through TLR4 and COX-2 pathways in the gastric AGS cells Known as a main immunomodulatory and gastroprotective cytokine produced and secreted via the COX-2/PGE2 pathway [16, 18, 20], IL-6 production was evaluated after the AGS cell treatment with HM along with LPS, using Western blot technology. After 72 h incubation, a concomitant increase in IL-6 protein expression was detected in the HM and LPS-treated cells, compared with the basal IL-6 expression level detected in the untreated cells (Figure 4A). The gene expression level of mucin 4, a mucosal extracellular matrix protein upregulated by IL-6 in gastric cancer cell lines [20], was significantly upregulated by HM (1.40-fold, p = 0.025) and LPS (1.52-fold, p = 0.031), compared with the basal mucin 4 gene expression level monitored in the untreated cells, the Control (Figure 4B). To explore the main pathways that could be involved in the HM-mediated IL-6 production, the TLR4 signaling pathway and COX-2 generation were blocked, using the pharmacological inhibitor TAK242, a TLR4 signaling pharmacological inhibitor and NS-398, a COX-2 inhibitor. We optimized of the optimal use of TAK242 and NS-398 pharmacological inhibitors, tested at various concentrations (0.1-100 mM), based on the phosphorylation of p65-NFkB, the main target of TLR4 signaling, and based on COX-2 generated, respectively. A clear decrease in the phospho-p65 NF-kB expression level (Figure 5A), as an indicator of TLR4 signaling blockade, and of COX-2 production (Figure 5B) was obtained after 2 h incubation of the cell pre-treatment with 1 mM TAK242 and 100 mM NS-398 followed by LPS stimulation for 48 h incubation, respectively. Throughout this experimental study with the pharmacological inhibitors, the cell pre-treatment with DMSO, which showed no cytotoxicity, was used as a negative control. The blockade of COX-2 generation using NS-398 decreased as expected the COX-2 protein expression in HM and LPS-treated AGS cells, as compared to the HM- and LPS-induced COX-2 protein expression (Figure 4E). A clear inhibition of the LPS and HM-induced COX-2 was also observed after the AGS cell pre-treatment with TLR4 signaling inhibitor TAK242 (Figure 5C). Regarding the LPS and HM-induced IL-6 protein expression level detected in the AGS cells, the blockade of TLR4 signaling using TAK242 significantly inhibited LPS and HM-induced IL-6, and the COX-2 inhibitor NS-398 impeded, to a higher extent, the IL-6 production induced by HM and LPS (Figure 5C). For the quantity of secreted PGE2 and IL-6, determined using specific ELISA kits, a significant increase of both secreted PGE2 and IL-6 induced by LPS and HM was observed (Figure 5D). The blockade of COX-2 production and of TLR4 signaling inhibited the LPS- and HM-induced PGE2 and IL-6 secretion in the human gastric cancer cell line AGS (Figure 5D). Discussion Current treatment strategies for gastric lesions are broadly associated with GI protective and damaging mechanisms. COX-2, PGE2 and IL-6 modulate various functions of the GI tract and have been widely implicated in gastric mucosal protective mechanisms [3, 19]. In recent years, there has been a growing interest in herbal therapies and in the use of natural plant products in traditional medicine to treat gastric lesions. Various studies demonstrated that many plants provide gastroprotection against various ulcerogens and accelerate ulcer healing [44, 45]. Nigella sativa (L.) plant, total extracts or constituents, is one of the traditional medicinal plants that demonstrated various anti-ulcerogenic effects in vivo , though the underlying molecular mechanisms remain elusive [46, 47]. In this study, we investigated the effects of herbal melanin (HM), extracted from the seed coats of the Nigella sativa (L.) plant, on COX-2, PGE2 and IL-6 production using the human gastric cancer cell line AGS. We showed that HM enhanced COX-2 expression, mucin 4 gene expression, and PGE2 and IL-6 secretion, hallmarks of gastroprotection. HM upregulated the gene and protein expression of its main receptor, TLR4. To identify the signaling pathway and investigate the underlying molecular mechanisms involved in HM-induced PGE2 and IL-6 production, the AGS cells were pre-treated with the TLR4 signaling inhibitor TAK242 and COX-2 inhibitor NS-398. An inhibition of HM-induced COX-2, PGE2 and IL-6 was observed in the TAK242 and NS-398-pre-treated AGS cells, indicating the role of TLR4 signaling and of COX-2 generated in HM biological effects. We conclude that HM acts through the TLR4/COX-2/PGE2 signaling pathway to induce IL-6 production and HM upregulates the mucin 4 gene expression in human gastric AGS cells, suggesting in vivo studies to demonstrate the gastroprotective protective action of HM at the biochemical level. COX enzymes synthesize PGE2 from arachidonic acid throughout the GI tract and mediate both protective and healing effects [3, 5]. In this study, the effect of HM on COX-2 expression in AGS cells was tested using RT-qPCR, Western blot technology and immune-cyto-fluorescence staining. The RT-qPCR data showed that HM increased the expression level of COX-2 in the AGS cells. Similarly, the Western blot analysis showed that the HM augmented COX-2 expression level in a time- and dose-dependent manner. The immunofluorescence staining confirmed these results and revealed the COX-2 expression in the nucleus, plasma membrane compartments, and predominantly localized in the cytoplasm and at the intercellular junctions upon HM treatment. In addition, we tested PGE2 secretion in the supernatant following HM/AGS treatment. Our ELISA results showed that HM increased PGE2 secretion in a time- and dose-dependent manner. As PGE2 is a direct downstream product of COX-2 [48], the ELISA results confirmed the effect of HM in the COX2 pathway activation. To further confirm that HM induced the COX-2 signaling pathway, AGS cells were pre-treated with the NS-398 COX-2 pharmacological inhibitor and the results showed a clear reduction in HM-induced COX-2 and PGE2, which indicate and confirm the direct role of HM in activating the COX2/PGE2 signaling pathway. The COX-2/PGE2 signaling pathway acts in combination with other signaling pathways such as the Ras-MAPK and NF-kB pathway and can be activated by different ligands of the TLRs family [15-17]. The role of TLR4 in activating the COX-2/PGE2 pathway in murine macrophages [49], intestinal epithelial cells [50], auditory cells [51], Barrett’s esophagus [52], and in human gastric carcinoma cells [53] has been reported. In the stomach, TLR4 is activated in response to pathogenic invasion, such as Helicabacter Pylori LPS, leading to the induction of COX-2 expression and PGE2 production in vivo [54]. The human gastric cell line AGS used in this study was reported to express the TLR4 receptor and the activation of the TLR4 signaling pathway induced by LPS was demonstrated [55]. Previously, we identified HM as a TLR4 ligand and observed a similarity between HM and LPS in TLR4 activation [36]. In the present study, the observed increased in COX-2 expression and PGE2 secretion by AGS after HM treatment was anticipated, similar to the HM effect on the TLR4/COX-2/PGE2 pathway activation. To confirm this assumption and provide evidence of the involvement of TLR4 in the observed results, both the TLR4 protein and mRNA expression levels were monitored. The AGS cells were treated in parallel, with HM at 5-10-20 mg/mL and LPS at 10 mg/mL and Western blot was performed after 72 h incubation. The results showed a clear TLR4 protein upregulation with all the HM concentrations tested or with LPS, as compared to the basal TLR4 expression level detected in untreated cells. Similarly, HM-induced TLR4 mRNA expression was confirmed after 24 h and 72 h incubation indicating the definite role of TLR4 in the HM biological effects. These findings agreed with the reported effects of different TLR4 ligands and COX2/PGE2 activation on gastric mucosa cells both in vitro and in vivo. Fukata and colleagues [10] reported that LPS induces TLR4/COX-2 expression in the epithelial cells and in lamina propria macrophages, which results in the upregulation of the mucosal PGE2. They proposed that this increased PGE2 expression might be required for mucosal restitution in response to epithelial injury [10]. Zheng et al . [56] reported that the administration of hyaluronic acid, another TLR4 ligand, activated the TLR4, induced COX-2 and subsequently PGE2. In addition, Chen et al. [57] showed that a high-molecular-weight hyaluronic acid protected against induced-gastrointestinal colitis via the activation of TLR4 and COX-2 and PGE2 expression. In these studies, the authors reported the implication of the different TLR4 ligands in the protective mechanism of the gastrointestinal tract, which suggests a similar gastroprotective role of HM. The effect of HM on IL-6 secretion and production by AGS cells was evaluated using ELISA and Western blot analysis. Our present results showed that HM treatment enhanced IL-6 secretion and production in the supernatant and cell lysates, respectively. We also showed that both the TLR4 inhibitor and the COX-2 inhibitor inhibited HM-induced IL-6 secretion and production. Our results indicated that HM induced IL-6 via the TLR4/COX-2/PGE2 signaling pathway in the AGS gastric cell line, which agreed with literature demonstrating the production of IL-6 via the activation of TLR4/COX-2/PGE2 pathway both in vitro and in vivo [58, 59]. IL-6 is a pleiotropic cytokine acting as a pro-inflammatory and anti-inflammatory cytokine, depending on its local concentration as well as the nature of the target cells [60, 61]. In the GI tract, IL-6 is expressed in the gastric, small intestinal and colonic mucosa epithelial cells and has been recognized as a multifaceted cytokine due to its opposing roles of promoting inflammation and malignancy or protecting and repairing effects [62]. In the stomach, IL-6 plays an important role in inducing cancer cell invasion and maintaining gastric homeostasis at the same time [17, 63]. Studies using mouse models, provided evidence supporting the beneficial roles of IL-6 signaling in protecting intestinal epithelial cells from apoptosis and maintaining the epithelial barrier integrity [64]. However, many studies related IL-6 overexpression to autoimmune diseases and cancer [65]. This controversy in the action of IL-6 has been demonstrated by Gradient et al. [66] who reported that IL-6 exerts completely opposite actions on neurons, triggering either neuronal survival after injury or causing neuronal degeneration and cell death in disorders such as Alzheimer's disease. In a previous in vivo study, we demonstrated that HM protected gastric epithelial cells from alcohol-, indomethacin-, aspirin-, stress-, and combined stress with aspirin-induced gastric ulcers [25]. Using human gastric cancer cell lines, Mejías-Luque et al. [20] demonstrated that IL-6 upregulates mucin 4 gene and protein expression levels. In this study, we have shown that HM induced IL-6 in the AGS gastric cell line and increased mucin 4 gene expression levels, which reinforces the HM gastroprotective potential. A blockade of IL-6 production and secretion would demonstrate whether HM upregulates mucin 4 gene expression in an IL-6-dependent manner. In spite of the recent advances indicating that IL-6 has multifaceted activities, and perhaps a beneficial role in protecting the GI tract from injuries, we cannot expect a protective role of IL-6. Additional in vivo studies are required to elucidate the exact role of HM-induced IL-6 in the stomach. Conclusions The current study is the first to demonstrate the stimulatory effect of the HM extracted from Nigella sativa (L.) black seed coats on the TLR4/COX-2 pathway in human gastric epithelial cells, resulting in the enhancement of the secretion of PGE2 and IL-6, accompanied by the upregulation of mucin 4 gene expression, three key players contributing to gastroprotection. Additional studies are warranted to investigate HM potential anti-ulcer activities in vivo . Abbreviations cDNA, complementary deoxyribonucleic acid; COX, cyclooxygenase; DMEM, Dulbecco’s modified Eagle medium; DMSO, dimethyl sulfoxide; ELISA, enzyme-linked immunosorbent assay; FBS, fetal bovine serum; FITC, fluorescein isothiocyanate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GI, gastrointestinal; HM, herbal melanin; LPS, lipopolysaccharide; NF-kB, nuclear factor kappa-light-chain-enhancer of activated B-cells; NSAIDs, nonsteroidal anti-inflammatory drugs; PBS, phosphate-buffered saline; PGE2, prostaglandin E2; RNA, ribonucleic acid; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; TLR, toll-like receptor; Declarations Ethics approval and consent to participate Not applicable Consent for publication Not applicable Availability of data and materials The datasets generated and analysed during the current study are available in the In vitro Gastroprotective effects of HM repository, doi:10.5061/dryad.ht76hdrj7. Competing interests The authors declare that there are no conflicts of interest. Funding All the carried out experiments were financially supported by King Abdullah International Medical Research Center (KAIMRC) under grant number RC15/080. Authors’ contributions AE and SMN conceived and conducted the study. YM, GA, MA, HA, NA, AHK and AH performed, generated the data, collected the data, and reviewed the manuscript. AE and SMN interpreted the data, wrote and reviewed the manuscript. Acknowledgements We are grateful to Dr Rizwan Ali from KAIMRC Medical Research Core Facility and Platforms for the use of the confocal scanner lasing microscope and for providing us the confocal images. References Chelakkot C, Ghim J, Ryu SH. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 2018;50:1-9. Wiertsema SP, van Bergenhenegouwen J, Garssen J, Knippels LMJ. The interplay between the gut microbiome and the immune system in the context of infectious diseases throughout life and the role of nutrition in optimizing treatment strategies. Nutrients 2021;13:886. Takeuchi K, Amagase K. Roles of cyclooxygenase, prostaglandin E2 and EP receptors in mucosal protection and ulcer healing in the gastrointestinal tract. Curr Pharm Des. 2018;24:2002-11. Smith WL, Urade Y, Jakobsson PJ. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem Rev. 2011;111:5821-65. Gudis K, Sakamoto C. The role of cyclooxygenase in gastric mucosal protection. Dig Dis Sci. 2005;50 Suppl. 1:S16-23. Miller TA. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol. 1983;245:G601-23. Rainsford KD. Gastrointestinal adaptation, gastrointestinal injury by NSAIDs. Regulation of eicosanoids and mucosal protection from NSAIDs. In: Rainsford KD, ed. Side eVects of anti-inflammatory drugs—4. Dordrecht: Kluwer Academic Publishers; 1997:197-205. Bjarnason I, Scarpignato C, Holmgren E, Olszewski M, Rainsford KD, Angel Lanas. Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs. Gastroenterology 2018;154:500–14. Burgueño JF, Abreu MT. Epithelial Toll-like receptors and their role in gut homeostasis and disease. Nat Rev Gastroenterol Hepatol. 2020;17:263-78. Fukata M, Chen A, Klepper A, Krishnareddy S, Vamadevan AS, Thomas LS, et al. Cox-2 is regulated by Toll-like Receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology 2006;131:862–77. Testro AG, Visvanathan K. Toll-like receptors and their role in gastrointestinal disease. J Gastroenterol Hepatol. 2009;24:943-54. Lavelle EC, Murphy C, O’Neill LAJ, Creagh EM. The role of TLRs, NLRs, and RLRs in mucosal innate immunity and homeostasis. Mucosal Immunol. 2010;3:17-28. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009;9:57–63 Slomiany BL, Slomiany A. Role of LPS-elicited signaling in triggering gastric mucosal inflammatory responses to H. pylori: modulatory effect of ghrelin. Inflammopharmacology 2017;25:415-29. Zhang Y, Chen H, Yang L. Toll-like receptor 4 participates in gastric mucosal protection through Cox-2 and PGE2. Dig Liver Dis. 2010;42:472-76. Wang P, Zhu F, Konstantopoulos K. Prostaglandin E2 induces interleukin-6 expression in human chondrocytes via cAMP/protein kinase A- and phosphatidylinositol 3-kinase-dependent NF-kB activation. Am J Physiol Cell Physiol. 2010;298:C1445-56. Guo Y, Wang B, Wang T, Gao L, Yang ZJ, Wang FF, et al. Biological characteristics of IL-6 and related intestinal diseases. Int J Biol Sci. 2021;17:204-19. Choy E, Rose-John S. Interleukin-6 as a multifunctional regulator: inflammation, immune response, and fibrosis. J Scleroderma Relat Discord. 2017;2:S1-5. Dann SM, Spehlmann ME, Hammond DC, Iimura M, Hase K, Choi LJ, et al. IL-6-dependent mucosal protection prevents establishment of a microbial niche for attaching/effacing lesion-forming enteric bacterial pathogens. J Immunol. 2008;180:6816-26. Mejías-Luque R, Peiró S, Vincent A, Van Seuningen I, de Bolós C. IL-6 induces MUC4 expression through gp130/STAT3 pathway in gastric cancer cell lines. Biochim Biophys Acta 2008;1783:1728-36. Santana FPR, Pinheiro NM, Mernak MIB, Righetti RF, Martins MA, Lago JHG, et al. Evidence of herbal medicine-derived natural products effects in inflammatory lung diseases. Mediators Inflamm. 2016;2016:2348968. Koshak AE, Yousif NM, Flebich BL, Koshak EA, Heinrich M. Comparative immunomodulatory activity of Nigella sativa L. preparations on proinflammatory mediators: A focus on asthma. Front. Pharmacol. 2018;9:1075. Dzobo K, Chiririwa H, Dandara C, Dzobo W. Coronavirus Disease-2019 treatment strategies targeting interleukin-6 signaling and herbal medicine. OMICS 2021;25:13-22. El-Tahir KEH, Hassib AM, El-Hag H, Pontén F, Westermark B, et al. Anti-ulcerogenic effects of Nigella sativa Melanin. 2009; Sudan Patent No. 1683. El-Obeid A, ELTahir KH, Elhag H, Haseeb AM. Anti-ulcerogenic Effects of Nigella sativa L. Melanin. World J Pharm Res 2016;5:1579-93. Khare CP. Encycopledia of Indian medicinal plants. NewYork: Springer-Verlag Berlin Heidelberg; 2004. Yimer EM, Tuem KB, Karim A, Ur-Rehman N, Anwar F. Nigella sativa L. (Black cumin): A promising natural remedy for wide range of illnesses. Evid Based Complement Alternat Med. 2019;2019:1528635. Majdalawieh AF, Fayyad MW. Recent advances on the anti-cancer properties of Nigella sativa, a widely used food additive. J Ayurveda Integr. Med. 2016;7:173-80. Maideen NMP. Antidiabetic activity of Nigella Sativa (Black seeds) and its active constituent (Thymoquinone): A review of human and experimental animal studies. Chonnam Med J. 2021;57:169-175. Rafati S, Niakan M, Naseri M. Anti-microbial effect of Nigella sativa seed extract against staphylococcal skin infection. Med J Islam Repub Iran 2014;28:42. Adam GO, Rahman MM, Lee SJ, Kim GB, Kang HS, Kim JS, et al. Hepatoprotective effects of Nigella sativa seed extract against acetaminophen-induced oxidative stress. Asian Pac J Trop Med. 2016;9:221-7 Pop RM, Sabin O, Suciu Ș, Vesa SC, Socaci SA, Chedea VS, et al. Nigella Sativa’s anti-inflammatory and antioxidative effects in experimental inflammation. Antioxidants (Basel) 2020;9:921. Hassib, 1998 Hassib, A., 1998. Extraction of melanin from Nigella sativa L. Patent No. 451, Khartoum, Sudan. El-Obeid A, Al-Harbi S, Al-Jomah N, Hassib A. Herbal melanin modulates tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) production. Phytomedicine 2006;13:324-33. El-Obeid A, Hassib A, Pontén F, Westermark B. Effect of herbal melanin on IL-8: a possible role of Toll-like receptor 4 (TLR4). Biochem Biophys Res Commun. 2006;344:1200-6. Öberg F, Haseeb A, Ahnfelt M, Pontén F, Westermark B, El-Obeid A. Herbal melanin activates TLR4/NF-kappaB signaling pathway. Phytomedicine 2009;16:477-84. El-Obeid A, Yahya WB, Almuzzaini B, Al Tuwaijri A, Najdi M, Hassib A, Matou-Nasri S. Herbal melanin induces interleukin-1b secretion and production by human THP-1 monocytes via Toll-like receptor 2 and p38 MAPK activation. Exp Ther Med. 2021;22:1081. El-Obeid A, Alajmi H, Harbi M, Yahya WB, Al-Eidi H, Alaujan M, et al. Distinct anti-proliferative effects of herbal melanin on human acute monocytic leukemia THP-1 cells and embryonic kidney HEK293 cells. BMC Complement Med Ther. 2020;20:154. Al-Obeed O, El-Obeid AS, Matou-Nasri S, Vaali-Mohammed MA, AlHaidan Y, Elwatidy M, et al. Herbal melanin inhibits colorectal cancer cell proliferation by altering redox balance, inducing apoptosis, and modulating MAPK signaling. Cancer Cell Int. 2020;20:126. Mimura T, Maeda K, Terada T, Oda Y, Morishita K, Aonuma S. Studies on biological activities of melanin from marine animals. III. Inhibitory effect of SM II (low molecular weight melanoprotein from squid) on phenylbutazone-induced ulceration in gastric mucosa in rats, and its mechanism of action. Chem Pharm Bull (Tokyo). 1985;33:2052-60. ElObeid AS, Kamal-Eldin A, Abdelhalim MAK, Haseeb AM. Pharmacological properties of melanin and its function in health. Basic Clin Pharmacol Toxicol. 2017;120:515-22. Konturek PC, Brzozowski T, Meixner H, Ptak A, Hahn EG, Konturek SJ. Central and peripheral neural aspects of gastroprotective and ulcer healing effects of lipopolysaccharides. J Physiol Pharmacol. 2001;52:611-23. Rameshbabu S, Messaoudi SA, Alehaideb ZI, Ali MS, Venktraman A, AlajmiH, et al. Anastatica hierochuntica (L.) methanolic and aqueous extracts exert antiproliferative effects through the induction of apoptosis in MCF-7 breast cancer cells. Saudi Pharm J 2020;28:985-993. Ryan SW. Management of dyspepsia and peptic ulcer disease. Altern Ther Health Med. 2005;11:26-29. Zayachkivska OS, Konturek SJ, Drozdowicz D, Konturek PC, Brzozowski T, Ghegotsky MR. Gastroprotective effects of flavonoids in plant extracts. J Physiol Pharmacol. 2005;56:219-31. El-Dakhakhny M., Mady N.I., Halim M.A. Nigella sativa L. oil protects against induced hepatotoxicity and improves serum lipid profile in rats. Arzneimittelforschung 2000;50:832-6. Kanter M, Demir H, Karakaya C, Ozbek H. Gastroprotective activity of Nigella sativa L. oil and its constituent, thymoquinone against acute alcohol-induced gastric mucosal injury in rats. World J Gastroenterol. 2005;11:6662-6. Giuliano F, Warner TD. Origins of prostaglandin E2: involvements of cyclooxygenase (COX)-1 and COX-2 in human and rat systems. J Pharmacol Exp Ther. 2002;303:1001-6. Zhang Y, Igwe OJ. Lipopolysaccharide (LPS)-mediated priming of toll-like receptor 4 enhances oxidant-induced prostaglandin E 2 biosynthesis in primary murine macrophages. Int Immunopharmacol. 2018;54:226-37. Fukata M, Chen A, Klepper A, Krishnareddy S, Vamadevan AS, Thomas LS, et al. Cox-2 is regulated by toll-like receptor-4 (TLR4) signaling and is important for proliferation and apoptosis in response to intestinal mucosal injury. Gastrointestinal 2006;131:862-77. Tanigawa T, Odkhuu E, Morikawa A, Hayashi K, Sato T, Shibata R, et al. Immunological role of prostaglandin E2 production in mouse auditory cells in response to LPS. Innate Immun. 2014;20:639-46. Verbeek RE, Siersema PD, Ten Kate FJ, Fluiter K, Souza RF, Vleggaar FP, et al. Toll-like receptor 4 activation in Barrett’s esophagus results in a strong increase in COX-2 expression. J Gastroenterol. 2014;49:1121-34. Schmausser B, Andrulis M, Endrich S, Müller-Hermelink HK, Eck M. Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol.2005;295:179-185. Scott T, Owens MD. Thrombocytes respond to lipopolysaccharide through Toll-like receptor-4, and MAP kinase and NF-kappaB pathways leading to expression of interleukin-6 and cyclooxygenase-2 with production of prostaglandin E 2 . Mol Immunol. 2008;45:1001-8. Su B, Ceponis PJM, Lebel S, Huynh H, Sherman PM. Helicobacter pylori activates Toll-like receptor 4 expression in gastrointestinal epithelial cells. Infect Immun. 2003;71:3496-502. Zheng L, Riehl T, Stenson WF. Regulation of colonic epithelial repair in mice by Toll-like receptors and hyaluronic acid. Gastroenterology 2009;137:2041-51. Chen H, Mahaseth M, Zhang Y. Hyaluronic acid as a rescue therapy for trinitrobenzene sulfonic acid-induced colitis through Cox-2 and PGE 2 in a Toll-like receptor 4-dependent way. J Zhejiang Univ Sci B. 2011;12:712-9. Lin CC, Lee IT, Yang YL, Lee CW, Kou YR, Yang CM. Induction of COX-2/PGE(2)/IL-6 is crucial for cigarette smoke extract-induced airway inflammation: Role of TLR4-dependent NADPH oxidase activation. Free Radic Biol Med. 2010;48:240-54. Raveendran VV, Tan X, Sweeney ME, Levant B, Slusser J, Stechschulte DJ, et al. Lipopolysaccharide induces H1 receptor expression and enhances histamine responsiveness in human coronary artery endothelial cells. Immunology 2011;132:578-88. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias, G, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 1998;187:461-8. Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, Aki D, et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol. 2003;4:551-6. Kuhn KA, Manieri NA, Liu TC, Stappenbeck TS. IL-6 stimulates intestinal epithelial proliferation and repair after injury. PLoS One 2014;9:e114195. Lin MT, Lin BR, Chang CC, Chu CY, Su HJ, Chen ST, et al. IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. Int J Cancer 2007;120:2600-8. Kuhn KA, Schulz HM, Regner EH, Severs EL, Hendrickson JD, Mehta G, et al. Bacteroidales recruit IL-6-producing intraepithelial lymphocytes in the colon to promote barrier integrity. Mucosal Immunol. 2018;11:357-68. Kumari N, Dwarakanath BS, Asmita D, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016;37:11553-72. Gadient RA, Otten UH. Interleukin-6 (IL-6)-- A molecule with both beneficial and destructive potentials. Prog Neurobiol. 1997;52:379-90. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Under Review Version 1 posted Editorial decision: Major revision 22 Nov, 2022 Reviews received at journal 18 Nov, 2022 Reviewers agreed at journal 10 Nov, 2022 Reviewers agreed at journal 16 Aug, 2022 Reviews received at journal 25 Jul, 2022 Reviewers agreed at journal 14 Jul, 2022 Reviewers invited by journal 15 May, 2022 Editor assigned by journal 10 May, 2022 Editor invited by journal 09 May, 2022 Submission checks completed at journal 09 May, 2022 First submitted to journal 26 Apr, 2022 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-1597711","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":104472002,"identity":"42dcbfbc-409c-4b0d-bbbb-f9617bd2a47b","order_by":0,"name":"Adila El-Obeid","email":"","orcid":"","institution":"KAIMRC, KSAU-HS","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Adila","middleName":"","lastName":"El-Obeid","suffix":""},{"id":104472003,"identity":"7f791af3-1e55-4a4b-be17-ef68abef034d","order_by":1,"name":"Yahya Maashi","email":"","orcid":"","institution":"King Faisal Medical City for Southern Region","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Yahya","middleName":"","lastName":"Maashi","suffix":""},{"id":104472004,"identity":"d5365cf2-771a-4cc1-bfd9-be2463346cac","order_by":2,"name":"Ghada Alatar","email":"","orcid":"","institution":"KAIMRC, KSAU-HS","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Ghada","middleName":"","lastName":"Alatar","suffix":""},{"id":104472005,"identity":"028bf4ba-4b1a-4da4-8b5e-4249ed19f176","order_by":3,"name":"Modhi Aljudayi","email":"","orcid":"","institution":"KAIMRC, KSAU-HS","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Modhi","middleName":"","lastName":"Aljudayi","suffix":""},{"id":104472006,"identity":"42229027-d3fd-450e-abea-a4691fc5b981","order_by":4,"name":"Hamad Al-Eidi","email":"","orcid":"","institution":"KAIMRC, KSAU-HS","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Hamad","middleName":"","lastName":"Al-Eidi","suffix":""},{"id":104472007,"identity":"d9217fe0-42d9-46b4-8a8d-aa3778ef3fb6","order_by":5,"name":"Nouf AlGaith","email":"","orcid":"","institution":"KAIMRC, KSAU-HS","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Nouf","middleName":"","lastName":"AlGaith","suffix":""},{"id":104472010,"identity":"c826b653-a399-46b4-9956-f93d56a33d20","order_by":6,"name":"Altaf Husain Khan","email":"","orcid":"","institution":"KAIMRC, KSAU-HS","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Altaf","middleName":"Husain","lastName":"Khan","suffix":""},{"id":104472011,"identity":"91416d36-3872-4aec-b85b-c72766f01a35","order_by":7,"name":"Adil Hassib","email":"","orcid":"","institution":"University of Khartoum","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Adil","middleName":"","lastName":"Hassib","suffix":""},{"id":104472012,"identity":"c9610c85-509e-4a37-86ef-447940542832","order_by":8,"name":"Sabine Matou-Nasri","email":"data:image/png;base64,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","orcid":"","institution":"KAIMRC, KSAU-HS","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Sabine","middleName":"","lastName":"Matou-Nasri","suffix":""}],"badges":[],"createdAt":"2022-04-26 14:44:22","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-1597711/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-1597711/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":21440133,"identity":"4e2e8146-26fd-40b2-a5a9-2ba78e687617","added_by":"auto","created_at":"2022-05-13 15:47:56","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":60464,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eHM upregulated TLR4 protein and gene expression levels in the human gastric cancer cell line AGS.\u003c/strong\u003e (A) Representative Western blot showing the stimulatory effect of HM and LPS on the TLR4 protein expression after 72 h exposure. GAPDH was used as a loading control. (B) Bar graph displaying the relative expression level of the TLR4 mRNA determined by RT-qPCR analysis in the AGS cells after 24 and 72 h incubation with 10 µg/mL of LPS or HM, compared with the untreated cells, calculated as a ratio of the expression to GAPDH mRNA. \u003csup\u003e*\u003c/sup\u003e\u003cem\u003ep\u003c/em\u003e \u0026lt; 0.05 and \u003csup\u003e**\u003c/sup\u003e\u003cem\u003ep\u003c/em\u003e \u0026lt; 0.01 compared with the control, from three independent experiments.\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-1597711/v1/dd249508996c4f834bf4aff4.png"},{"id":21440134,"identity":"6c39bf24-992f-4567-b3c2-ee91b0f7e723","added_by":"auto","created_at":"2022-05-13 15:47:56","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":298664,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eHM increased COX-2 protein and gene expression levels in the gastric AGS cells.\u003c/strong\u003e\u0026nbsp;(A) Representative Western blot showing the stimulatory effect of both LPS and HM on COX-2 protein expression in the untreated AGS cells and the cells treated after 72 h incubation. The bar graph shows the relative expression levels of COX-2, calculated as a ratio of the expression to GAPDH. (B) Bar graph showing the relative expression level of COX-2 mRNA determined by RT-qPCR analysis in the AGS cells after 24, 48 and 72 h incubation with 10 µg/mL of LPS or HM, compared with the untreated treated cells, calculated as a ratio of the expression to GAPDH mRNA. \u003csup\u003e*\u003c/sup\u003e\u003cem\u003ep\u003c/em\u003e \u0026lt; 0.05 and \u003csup\u003e**\u003c/sup\u003e\u003cem\u003ep \u003c/em\u003e\u0026lt; 0.01 compared with the control, from three independent experiments. (C) Representative photomicrographs of the immunochemistry staining of COX-2 expression targeted by monoclonal anti-COX-2 conjugated to FITC, revealing the COX-2 nuclear, cytoplasmic, plasma membrane, and intercellular junctions localizations in the untreated AGS cells and cells exposed to 10 mg/mL of LPS or HM after 24, 48 and 72 h incubation. A higher magnification of an example of the AGS cells depicted in the insert including the arrows pointing to the different COX-2 cellular localizations as “C” standing for cytoplasmic, “P” for plasma membrane-bound form, “N” for nuclear, and “I” for intercellular junctions. Scale bar = 5 mm. (D) Bar graph showing the arbitrary quantification of the COX-2 protein expression levels analyzed using ImageJ software (from 6 random fields) at the cellular compartments after 72 h incubation, compared to the COX-2 expression level measured in the untreated cells, the control. \u003csup\u003e*\u003c/sup\u003e\u003cem\u003ep\u003c/em\u003e \u0026lt; 0.05, \u003csup\u003e**\u003c/sup\u003e\u003cem\u003ep \u003c/em\u003e\u0026lt; 0.01, \u003csup\u003e***\u003c/sup\u003e\u003cem\u003ep \u003c/em\u003e\u0026lt; 0.001, and \u003csup\u003e****\u003c/sup\u003e\u003cem\u003ep \u003c/em\u003e\u0026lt; 0.0001 compared with the control, from three independent experiments.\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-1597711/v1/0352e39cd4f6159138bc8940.png"},{"id":21440137,"identity":"8ea6357b-7a00-44c1-8578-d7267860b021","added_by":"auto","created_at":"2022-05-13 15:47:56","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":46051,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eHM enhanced PGE2 secretion released by the gastric AGS cells.\u003c/strong\u003e Bar graph showing the concentration of the secreted PGE2 determined using an ELISA assay in the collected media of the cultured AGS cells following to 4, 24, 48, and 72 h exposure to 10 mg/mL LPS or 5-10-20 mg/mL HM. \u003csup\u003e*\u003c/sup\u003e\u003cem\u003ep\u003c/em\u003e \u0026lt; 0.05, \u003csup\u003e**\u003c/sup\u003e\u003cem\u003ep \u003c/em\u003e\u0026lt; 0.01, and\u003csup\u003e ***\u003c/sup\u003e\u003cem\u003ep \u003c/em\u003e\u0026lt; 0.001 compared with the corresponding control, from three independent experiments.\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-1597711/v1/97f0273df10e399d1cbe109e.png"},{"id":21440135,"identity":"a8890f0a-c00a-4df5-9eea-6a7109e2ebfb","added_by":"auto","created_at":"2022-05-13 15:47:56","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":56631,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eHM upregulated IL-6 and mucin 4 production by the gastric AGS cells.\u003c/strong\u003e (A) Representative Western blot showing the stimulatory effect of 10 mg/mL of LPS and HM on IL-6 protein expression. a-Tubulin was used as a loading control. (B) Bar graph showing the relative expression level of Mucin 4 mRNA determined by RT-qPCR analysis in the AGS cells after 72 h incubation with 10 µg/mL of LPS or HM, compared with the untreated cells, calculated as a ratio of the expression to GAPDH mRNA. \u003csup\u003e*\u003c/sup\u003e\u003cem\u003ep\u003c/em\u003e \u0026lt; 0.05 compared with the control, from three independent experiments.\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e","description":"","filename":"4.png","url":"https://assets-eu.researchsquare.com/files/rs-1597711/v1/4667c6fa73a0d1a3003240cd.png"},{"id":21440136,"identity":"3461a8fe-9874-44b3-ab74-150e88a26313","added_by":"auto","created_at":"2022-05-13 15:47:56","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":89705,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eHM-induced IL-6 production and secretion through TLR4 signaling and COX-2 generation by the gastric AGS cells.\u003c/strong\u003e (A) Optimization of the optimal concentration of the TLR4 signaling pharmacological inhibitor TAK242 for the blockade of TLR4 signaling, based on the loss of phosphorylation of p65 NFkB, its main downstream target. Total p65 NFkB was used as a loading control. (B) Optimization of the optimal concentration of the COX-2 pharmacological inhibitor for the blockade of COX-2 production, based on the decrease of COX-2 expression. a-Tubulin was used as a loading control. (C) Representative Western blot and bar graph showing and summarizing the impact of the blockade of TLR4 signaling (using TAK242) and of COX-2 inhibitor (NS-398) on LPS- and HM-induced COX-2 and IL-6 production in the AGS cells after 72 h incubation, as compared with LPS- and HM-induced COX-2 and IL-6 production in AGS cells-pretreated with DMSO (solvent used for TAK242 and NS-398 reconstitution). (D) Bar graph showing the impact of the blockade of TLR4 signaling (using TAK242) and of COX-2 inhibitor (NS-398) on the LPS- and HM-induced secreted PGE2 and IL-6 released by AGS cells after 72 h incubation, detected in the conditional media using an ELISA. \u003csup\u003e*\u003c/sup\u003e\u003cem\u003ep\u003c/em\u003e \u0026lt; 0.05, \u003csup\u003e**\u003c/sup\u003e\u003cem\u003ep \u003c/em\u003e\u0026lt; 0.01, and \u003csup\u003e***\u003c/sup\u003e\u003cem\u003ep \u003c/em\u003e\u0026lt; 0.001 compared with the control, from three independent experiments.\u003c/p\u003e","description":"","filename":"5.png","url":"https://assets-eu.researchsquare.com/files/rs-1597711/v1/1eebe5ec99fa657434508ed8.png"},{"id":21440138,"identity":"77377d92-c519-42bc-8ca4-3d081010498d","added_by":"auto","created_at":"2022-05-13 15:47:59","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":593742,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-1597711/v1/1b1c3478-2590-4c78-9f0a-2f3c718079d7.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Herbal melanin modulates PGE2 and IL-6 gastroprotective markers through COX-2 and TLR4 signaling in the gastric cancer cell line AGS","fulltext":[{"header":"Introduction ","content":"\u003cp\u003eThe structural and functional integrity of the intestinal mucosa (\u003cem\u003ei.e\u003c/em\u003e., epithelium lining the gastrointestinal (GI) tract) are naturally maintained by the balance between aggressive forces and protective mechanisms [1]. The intestinal mucosa layer\u0026nbsp;provides a physical barrier and is the first line of immunological defense against invasion by bacteria, viruses and harmful endogenous macromolecules [1].\u0026nbsp;Multiple defense mechanisms protect the GI tract, including the mucus gel layer, intercellular tight junctions, mucosal nerves and toll-like receptors (TLRs) [1, 2]. Cyclooxygenase 2 (COX-2) and prostaglandin E2 (PGE2) play a crucial role in mucosal protection [3]. COX-2 and COX-1 proteins are both isoforms of\u0026nbsp;cyclooxygenase (COX) that catalyze PGE2 biosynthesis from arachidonic acid, following its release from the plasma membrane via phospholipase A2 [4].\u0026nbsp;COX is expressed by the normal gastric mucosa. It contributes to the preservation of the mucosal integrity via PGE2 production [5].\u0026nbsp;Well known as a mediator of inflammation that regulates tissue regeneration, PGE2 is one of the most important biologically active prostanoids found throughout the GI tract for its physiological functions, including GI secretions and motility [3, 6]. The inhibition of COX-2 and PGE2 causes a decrease in mucus and bicarbonate secretion, reduces mucosal blood flow, and causes vascular injury resulting in mucosal damage [3, 7]. A growing body of experimental and clinical evidence suggests that gastric mucosal damage is mediated through\u0026nbsp;the inhibition of COX-2 and PGE2 by nonsteroidal anti-inflammatory drugs (NSAIDs) [8].\u003c/p\u003e\n\u003cp\u003eThe activation of the COX-2/PGE2 signaling pathway via TLRs has been reported in the GI tract [9, 10]. TLRs are members of a superfamily of transmembrane receptors that recognize pathogen-associated molecular patterns and are a subset of pathogen-recognition receptors.\u0026nbsp;The expression of TLRs has been detected in the GI tract in the\u0026nbsp;epithelial cells, lamina propria, dendritic and Paneth cells [11]. The TLRs expressed on the gastric mucosa are constantly exposed and activated by microbial ligands produced by pathogenic and commensal bacteria. It is acknowledged that the interaction between the gut microbiota and the local TLRs support the maintenance of homeostasis in the GI tract [12]. Various studies demonstrated the expression and activation of TLR4 by bacterial lipopolysaccharide (LPS) in the intestinal mucosa [13, 14]. In addition, the activation of the TLR4/COX-2 and of TLR4/NF-kB signaling pathways induce PGE2 and interleukin (IL)-6 production, respectively, resulting in gastric mucosal protection [15-17].\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe IL-6 cytokine, originally identified as a B-cell\u0026ndash;stimulating factor 2, is mainly known as an important induced inflammatory modulator, which exerts\u0026nbsp;inhibitory and stimulatory effects on the innate and adaptive immune cells at certain levels of inflammation, in response to infection or tissue injury [17, 18]. IL-6 has pleiotropic activities, which contribute to gastric homeostasis through the regulation of metabolic and regenerative processes, including mucosal repairing\u0026nbsp;[17]. In addition, IL-6\u0026nbsp;protects the mucosa against ulceration and upregulate mucin 4 expression in cultured gastric cancer cell lines [19, 20]. Numerous studies reported the effects of medicinal natural products, including \u003cem\u003eNigella sativa\u003c/em\u003e L. extracts, on antigen-presenting cells stimulating the release of key cytokines such as IL-6, suggesting a beneficial gastroprotective effect of the natural products for the prevention and the treatment of inflammatory diseases, including stomach ulcers [21-25].\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eHerbal melanin (HM) has been extracted from \u003cem\u003eNigella sativa\u0026nbsp;\u003c/em\u003eL. (Black cumin), an annual herbaceous plant in the family Ranunculaceae that widely grows in the Mediterranean countries, Western Asia, Southern Europe, and Middle East [26]. This plant is considered as one of the greatest traditional healing herb and numerous research has been carried out on its medicinal properties [27], such as anticancer [28], antidiabetic [29], antimicrobial [30], hepatoprotective [31], anti-inflammatory and antioxidant [32] agent. HM has been presented as a macromolecule of a heterogeneous polymer mainly composed of 5,6-dihydroxyindole (DHI) and 5,6-dihydroxyindole-2-carboxylic acid (DHICA) [33, 34]. In addition, HM was demonstrated to act via TLRs (i.e., TLR4, its main receptor, and TLR2) leading to NF-kB and p38 MAPK activation, which result in interleukins (\u003cem\u003ei.e\u003c/em\u003e., IL-8, IL-6, IL-1b) and vascular endothelial growth factor production by human monocytes [35-37]. High HM concentrations exert antiproliferative effects in human monocytic, embryonic kidney and colorectal cancer cell lines through induction of apoptosis [38, 39]. Various studies revealed beneficial effects of melanin on gastric health [40, 41]. We previously reported that HM acts as a strong anti-ulcerogenic agent against gastric ulcers induced in rats [24, 25], suggesting a protective action of HM in the gastrointestinal tract. However, the underlying molecular mechanisms contributing to the beneficial gastroprotective effects of HM remain elusive. In the current study, we investigated the gastroprotective effects of HM based on TLR4/COX2 expression, PGE2 and IL-6 secretion using the gastric cancer cell line AGS.\u003c/p\u003e"},{"header":"Materials and Methods","content":"\u003cp\u003e\u003cstrong\u003eReagents\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eHerbal melanin (HM) was extracted from\u0026nbsp;\u003cem\u003eNigella sativa\u003c/em\u003e L. seed coats that were purchased from a local public herbarium in Riyadh (Saudi Arabia). HM was prepared, analyzed and characterized as previously described in [33, 34]. HM was well solubilized in distilled water and the presence of endotoxins in the HM solution was below the detection level, using a fluorogenic endotoxin test (Lonza Verviers SPRL, Verviers, Belgium). Culture media and reagents were procured from Gibco\u0026reg; (Thermo Fisher Scientific Inc., Waltham, MA, USA). Lipopolysaccharides (LPS, purified from \u003cem\u003eE. Coli\u003c/em\u003e)\u0026nbsp;and dimethyl sulfoxide (DMSO)\u0026nbsp;were provided by Sigma-Aldrich Corp (St. Louis, MO). COX-2 specific NS-398 pharmacological inhibitor (#sc-200604) was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX). TLR4 signaling TAK242 pharmacological inhibitor (#6587/5) was procured from Tocris Bioscience\u0026trade; (Bristol, UK).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCell culture and treatment\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe human gastric cancer cell line AGS (#CRL-1739\u0026trade;) was purchased from the American Type Culture Collection (Manassas, VA, USA). The AGS cells were cultured in complete medium composed of Dulbecco\u0026apos;s Modified Eagle\u0026apos;s Medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 1% antibiotics (100\u0026nbsp;mg/mL streptomycin, 100 IU/mL penicillin). The cells were cultured at 37\u0026deg;C in a humidified 5% CO2-incubator. Reaching 80-90% confluence, the cells were trypsinized and split in a ratio of 1:3 for each passage. Between passage 3 and 8, the cells were used for downstream applications.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe cells were treated with either LPS tested at 10\u0026nbsp;mg/mL, dose reported to exhibit \u003cem\u003ein vivo\u003c/em\u003e gastroprotective effects [42], or with various concentrations (5-10-20\u0026nbsp;mg/mL) of HM at different incubation time periods (4-24-48-72 h).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eProtein sample preparation and Western blot technology\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe AGS cells (5\u0026times;10\u003csup\u003e5\u003c/sup\u003e cells) were seeded in complete medium in 12-well plates. The next day, the cells were incubated in the absence (the Control) or in the presence of either 10 mg/mL LPS or 5-10 and 20 \u0026micro;g/mL of HM, for different incubation time periods (24, 48, and 72 h). The cells were then trypsinized, washed and centrifuged at high-speed. The cell pellet was lysed using the NP40 lysis buffer (Invitrogen, Carlsbad, CA, USA) and the extracted protein samples were estimated using the Invitrogen Qubit\u0026trade; Protein Assay kit according to the manufacturer\u0026rsquo;s instructions. The Western blot technology and analysis were done as described in [43] for the detection of COX-2, IL-6, TLR4, phospho-p65 NFkB, and total p65 NF-kB using goat anti-COX-2 antibody (#AF4198, R\u0026amp;D systems, Minneapolis, MN, USA), rabbit polyclonal anti-IL-6 antibody (#TA328217, OriGene Technologies Inc., Rockville, MD, USA), rabbit monoclonal anti-TLR4 antibody (#ab13867, Abcam, Cambridge, UK), rabbit monoclonal phospho-p65 (Ser 529) NF-kB (#44711G, Invitrogen, Thermo Fischer Scientific) and mouse monoclonal anti-p65 NF-kB (#sc-8008, Santa Cruz Biotechnology), respectively. Mouse monoclonal anti-GAPDH (#ab8245, Abcam) and rabbit monoclonal anti-a-Tubulin (#ab13867, Abcam) antibodies were used for the detection of the housekeeping proteins glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and a-Tubulin, used as loading controls. The Western blots were scanned and analyzed using an Odyssey CLx Scanner (LI-COR Biosciences, Lincoln, NE, USA) and ImageJ software (https://imagej.nih.gov/ij/download.html).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEnzyme-Linked Immunosorbent Assay (ELISA)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe AGS cells (1\u0026times;\u0026nbsp;10\u003csup\u003e6\u003c/sup\u003e) were seeded in complete medium in 12-well plate.\u0026nbsp;The next day, the cells were incubated in the absence (the Control) or in the presence of either 10\u0026nbsp;mg/mL LPS or 5-10 and 20 \u0026micro;g/mL of HM, for different incubation time periods (4, 24, 48, and 72 h).\u0026nbsp;The levels of PGE2 and IL-6 secreted in the supernatant were determined by ELISA. Human Prostaglandin E2 ELISA kit (#ADI-900-001, Enzo Life Sciences Inc., Farmingdale, NY, USA), R\u0026amp;D systems Prostaglandin E2 Assay Parameter\u003csup\u003e\u0026trade;\u003c/sup\u003e Assay kit (#KGE004B) and the human IL-6 Immunoassay Quantikine ELISA kit (#D6050, R\u0026amp;D systems) were used following the manufacturers\u0026rsquo; instructions. The untreated cells, cultured in complete medium, were used as controls. Triplicate readings for each standard, control and sample were recorded as previously described in [33] and measured using a Molecular Devices\u0026nbsp;SpectraMax\u0026reg; Plus 384 microplate reader.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eRNA extraction and RT-qPCR\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eTotal RNA\u0026nbsp;extraction was carried out from the untreated and treated cells (1\u0026times;\u0026nbsp;10\u003csup\u003e6\u003c/sup\u003e)\u0026nbsp;using the Qiagen RNeasy Mini Kit (Qiagen Inc., Fisher Scientific,\u0026nbsp;Pittsburg, PA,\u0026nbsp;USA) according to the manufacturer\u0026rsquo;s protocol. The RNA extract was reverse-transcribed to cDNA,\u0026nbsp;and RT-qPCR was performed as previously described in [38].\u0026nbsp;The primer pair sequences (Invitrogen,\u0026nbsp;Thermo Fisher Scientific) used were 5\u0026apos;-AGATCATCTCTGCCTGAGTATCTT-3\u0026apos; (forward) and 5\u0026apos;-TTCAAATGAGATTGTGGGAAAAT-3\u0026apos; (reverse) for human \u003cem\u003eCOX-2\u003c/em\u003e gene;\u0026nbsp;5\u0026prime;-GAA GCT GGT GGC TGT GGA-3\u0026prime;\u0026nbsp;(forward) and 5\u0026prime;-TGA TGT AGA ACC CGC AAG-3\u0026prime;\u0026nbsp;(reverse) for\u0026nbsp;human \u003cem\u003eTLR4\u0026nbsp;\u003c/em\u003egene. For the human \u003cem\u003eMUC4\u003c/em\u003e gene, the primer pair sequences (Macrogen Inc., Seoul, South Korea) used were 5\u0026apos;-GCTTACTTCAGATGCGATG-3\u0026apos; (forward) and 5\u0026apos;-GTCGAGTTTCATGCTCAGG-3\u0026apos; (reverse). The gene expression levels were monitored using an Applied Biosystems\u0026trade; 7500 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA) and were detected, calculated and normalized to the expression of the housekeeping gene \u003cem\u003eGAPDH\u003c/em\u003e, as described previously in [38].\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eImmunofluorescence staining\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe AGS cells (5\u0026times;10\u003csup\u003e3\u003c/sup\u003e cells) were seeded on a Nunc\u0026reg; Lab-Tek\u0026trade; II chambered cover glass. The next day, the cells were exposed to either 10\u0026nbsp;mg/mL HM or 10\u0026nbsp;mg/mL LPS at different incubation time periods (24, 48 and 72 h). After the incubation, the cells were rinsed with PBS, then fixed for 30 min at room temperature with 4% formaldehyde diluted in PBS, and the membrane permeabilization was done using 0.1 % Triton X-100 in PBS for 10 min, at room temperature. For COX-2 detection, the cells were mixed with either Santa Cruz Biotechnology fluorescein isothiocyanate (FITC)-conjugated mouse IgG1 (#sc-2855, used as a negative control, data not shown) or FITC-conjugated anti-human/mouse COX-2 antibody (#sc-19999). The immunofluorescence staining was captured using LSM780 confocal scanner lasing microscope (Carl Zeiss Microscopy GmbH, Jena, Germany).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTLR4 signaling and COX-2 generation blockade\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eTo investigate whether HM acts through TLR4 signaling activation and COX-2 generation for the stimulation of IL-6 production/secretion and of PGE2 secretion, the AGS cells were treated with TAK242 and NS-398, used as specific pharmacological inhibitors of TLR4 signaling and COX-2, respectively. Briefly, the AGS cells (1\u0026times;\u0026nbsp;10\u003csup\u003e6\u003c/sup\u003e) were seeded in complete medium in a 12-well plate. The next day, the medium was renewed with 1\u0026nbsp;mM TAK242, 100\u0026nbsp;mM NS-398 (both were reconstituted in DMSO and concentration was fixed from optimization) and with 1% DMSO (corresponding to the highest pharmacological inhibitor concentration tested), used as a negative control. After 2 h incubation, the cells were exposed to either 10\u0026nbsp;mg/mL of HM or LPS for a further 72-h incubation, followed by supernatant collection for ELISA and protein extraction for Western blot technology.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStatistical analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll the data are expressed as mean \u0026plusmn; standard deviation (SD) based on three independent experiments. A one-way ANOVA test was used for comparison of the two groups. The generalized estimating equations (GENMOD procedure) from SAS software was applied to compare the protein expression level between and within each treatment at the various exposure times. Each pairwise comparison was performed using a post-hoc Tukey test. Values of \u003cem\u003ep\u003c/em\u003e \u0026lt; 0.05 were considered significant.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003e\u003cstrong\u003eHM upregulated TLR4 and COX-2 expression levels in the human gastric AGS cells\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eTLR4 receptor is known as the main receptor for both LPS and HM, and COX-2 plays a key role in gastric mucosal protection [3, 35]. We monitored the protein and gene expression levels of TLR4 and COX-2 in the AGS cells after 72 h exposure to 5-10-20 mg/mL HM and 10 mg/mL LPS, using Western blot technology and RT-qPCR. A significant increase in the TLR4 protein expression was observed in the AGS cells treated with all HM concentrations (2.5-fold, \u003cem\u003ep\u003c/em\u003e \u0026lt; 0.01) and with LPS (3.11-fold, \u003cem\u003ep\u003c/em\u003e = 0.037), compared with the basal TLR4 expression level detected in untreated cells (Figure 1A). Monitored at 24 h and 72 h incubation, the HM-induced TLR4 expression was also confirmed at the gene expression level, compared to the untreated cells (Figure 1B).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAs depicted in Figure 2A, compared to the COX-2 basal expression level detected in the untreated AGS cells, the LPS significantly increased (2.25-fold, \u003cem\u003ep\u003c/em\u003e = 0.015) the COX-2 expression level, and a dose-dependent effect of HM-induced COX-2 protein expression was observed reaching a peak of stimulation (4.47-fold, \u003cem\u003ep\u003c/em\u003e = 0.0014) at 10 mg/mL of HM (Figure 2A). The COX-2 gene expression level was monitored in the untreated AGS cells and in the cells treated with either 10 mg/mL LPS or HM at different incubation time periods (24-48-72 h). Compared to the basal COX-2 expression levels detected in the untreated cells, a slight increase (1.2- and 1.5-fold, \u003cem\u003ep\u003c/em\u003e \u0026lt; 0.05) in the COX-2 gene expression levels was induced by the LPS at 24 h and 48 h incubation and a concomitant enhancement (3.0-fold, \u003cem\u003ep\u003c/em\u003e \u0026lt; 0.05) was observed after 72 h incubation of the cell treatment with LPS (Figure 3B). After 24 h incubation, HM did not change the COX-2 gene expression level, but a significant increase in the COX-2 gene expression level was observed after 48 h (3.2-fold, \u003cem\u003ep\u003c/em\u003e \u0026lt; 0.01) and after 72 h (2.8-fold, \u003cem\u003ep\u003c/em\u003e \u0026lt; 0.01) of incubation of the AGS cells treated with 10 mg/mL of HM, compared with untreated cells (Figure 2B). Using immunofluorescence staining, representative photomicrographs of the AGS cells incubated with the monoclonal antibody directed against COX-2 conjugated to FITC showed the diverse cellular localizations of COX-2 expressed after 24-48-72 h of cell treatment with 10 mg/mL of LPS or HM. The COX-2 localization was revealed to be in nuclear, cytoplasmic, plasma membrane compartments, and at the intercellular junctions (Figure 2C). After 72 h incubation, significant increases in intercellular junctions-bound COX-2 and cytoplasmic COX-2 expression levels were observed in the AGS cells treated with HM, to a higher extent than the LPS effect (Figure 2D). Slight significant enhancements of the plasma membrane-bound COX-2 and nuclear COX-2 expression levels were induced by LPS. However, the AGS cell treatment with HM resulted in a significant increase in the plasma membrane-bound COX-2 expression levels, as compared with the cellular localization of COX-2 expression levels determined in the untreated cells, the Control (Figure 2D).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eHM enhanced PGE2 secretion from the gastric AGS cells\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWith COX-2 described to mediate PGE2 production, the AGS cell culture supernatants were collected after 4-24-48-72 h of treatment with 5-10-20 mg/mL of HM along with 10 mg/mL LPS. After 4 h incubation, a significant increase (1.8-fold, \u003cem\u003ep\u003c/em\u003e = 0.0006) in secreted PGE2 concentration was observed after the AGS cell exposure to HM. The LPS did not change the secreted PGE2 production as compared with the basal level of the secreted PGE2 detected in untreated AGS cell culture supernatant collected at 4 h incubation (Figure 3). A gradual increase in the secreted PGE2 was observed over the incubation time of the AGS cell exposure to different HM concentrations, significant (\u003cem\u003ep\u003c/em\u003e \u0026lt; 0.0001) at 48 h incubation (2.56-fold increase at 10 mg/mL) and 72 h incubation (3.29-fold increase at 10 mg/mL), compared with the basal level of secreted PGE2 detected in untreated cells after 4 h incubation (Figure 3). A concomitant increase (3.96-fold, \u003cem\u003ep\u0026nbsp;\u003c/em\u003e\u0026lt; 0.0001) of secreted PGE2 was induced by the LPS after 72 h incubation, compared with the basal level of secreted PGE2 (Figure 4). Of note, no significant increase of the secreted PGE2 was revealed after the addition of HM (tested at all concentrations) and even after the cell treatment with LPS over 48 h incubation, as compared with the amount of secreted PGE2 released from untreated cells after 48 h incubation (Figure 3). However, after 72 h incubation, both the HM (\u003cem\u003ep\u003c/em\u003e = 0.0324) and the LPS (\u003cem\u003ep\u003c/em\u003e = 0.0005) tested at 10 mg/mL significantly enhanced the PGE2 secretion by the AGS cells, compared with the amount of secreted PGE2 released from the untreated cells after 72 h incubation (Figure 3).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eHM upregulated mucin 4 gene expression levels and induced PGE2 and IL-6 production and secretion through TLR4 and COX-2 pathways in the gastric AGS cells\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eKnown as a main immunomodulatory and gastroprotective cytokine produced and secreted via the COX-2/PGE2 pathway [16, 18, 20], IL-6 production was evaluated after the AGS cell treatment with HM along with LPS, using Western blot technology. After 72 h incubation, a concomitant increase in IL-6 protein expression was detected in the HM and LPS-treated cells, compared with the basal IL-6 expression level detected in the untreated cells (Figure 4A). The gene expression level of mucin 4, a mucosal extracellular matrix protein upregulated by IL-6 in gastric cancer cell lines [20], was significantly upregulated by HM (1.40-fold, \u003cem\u003ep\u003c/em\u003e = 0.025) and LPS (1.52-fold, \u003cem\u003ep\u003c/em\u003e = 0.031), compared with the basal mucin 4 gene expression level monitored in the untreated cells, the Control (Figure 4B).\u003c/p\u003e\n\u003cp\u003eTo explore the main pathways that could be involved in the HM-mediated IL-6 production, the TLR4 signaling pathway and COX-2 generation were blocked, using the pharmacological inhibitor TAK242, a TLR4 signaling pharmacological inhibitor and NS-398, a COX-2 inhibitor. We optimized of the optimal use of TAK242 and NS-398 pharmacological inhibitors, tested at various concentrations (0.1-100 mM), based on the phosphorylation of p65-NFkB, the main target of TLR4 signaling, and based on COX-2 generated, respectively. A clear decrease in the phospho-p65 NF-kB expression level (Figure 5A), as an indicator of TLR4 signaling blockade, and of COX-2 production (Figure 5B) was obtained after 2 h incubation of the cell pre-treatment with 1 mM TAK242 and 100 mM NS-398 followed by LPS stimulation for 48 h incubation, respectively. Throughout this experimental study with the pharmacological inhibitors, the cell pre-treatment with DMSO, which showed no cytotoxicity, was used as a negative control. The blockade of COX-2 generation using NS-398 decreased as expected the COX-2 protein expression in HM and LPS-treated AGS cells, as compared to the HM- and LPS-induced COX-2 protein expression (Figure 4E). A clear inhibition of the LPS and HM-induced COX-2 was also observed after the AGS cell pre-treatment with TLR4 signaling inhibitor TAK242 (Figure 5C). Regarding the LPS and HM-induced IL-6 protein expression level detected in the AGS cells, the blockade of TLR4 signaling using TAK242 significantly inhibited LPS and HM-induced IL-6, and the COX-2 inhibitor NS-398 impeded, to a higher extent, the IL-6 production induced by HM and LPS (Figure 5C). For the quantity of secreted PGE2 and IL-6, determined using specific ELISA kits, a significant increase of both secreted PGE2 and IL-6 induced by LPS and HM was observed (Figure 5D). The blockade of COX-2 production and of TLR4 signaling inhibited the LPS- and HM-induced PGE2 and IL-6 secretion in the human gastric cancer cell line AGS (Figure 5D).\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eCurrent treatment strategies for gastric lesions are broadly associated with GI protective and damaging mechanisms. COX-2, PGE2 and IL-6\u0026nbsp;modulate various functions of the GI tract\u0026nbsp;and have been widely implicated in gastric mucosal protective mechanisms\u0026nbsp;[3, 19].\u0026nbsp;In recent years, there has been a growing interest in herbal therapies and in the use of natural plant products in traditional medicine to treat gastric lesions. Various studies demonstrated that many plants provide gastroprotection against various ulcerogens and accelerate ulcer healing [44, 45].\u0026nbsp;\u003cem\u003eNigella sativa\u003c/em\u003e (L.) plant, total extracts or constituents, is one of the traditional medicinal plants that demonstrated various anti-ulcerogenic effects \u003cem\u003ein vivo\u003c/em\u003e, though the underlying molecular mechanisms remain elusive [46, 47]. In this study, we investigated the effects of herbal melanin (HM), extracted from the seed coats of the \u003cem\u003eNigella sativa\u003c/em\u003e (L.) plant, on COX-2, PGE2 and IL-6 production using the human gastric cancer cell line AGS. We showed that HM enhanced COX-2 expression, mucin 4 gene expression, and PGE2 and IL-6 secretion, hallmarks of gastroprotection. HM upregulated the gene and protein expression of its main receptor, TLR4. To identify the signaling pathway and investigate the underlying molecular mechanisms involved in HM-induced PGE2 and IL-6 production, the AGS cells were pre-treated with the TLR4 signaling inhibitor TAK242 and COX-2 inhibitor NS-398. An inhibition of HM-induced COX-2, PGE2 and IL-6 was observed in the TAK242 and NS-398-pre-treated AGS cells, indicating the role of TLR4 signaling and of COX-2 generated in HM biological effects. We conclude that HM acts through the TLR4/COX-2/PGE2 signaling pathway to induce IL-6 production and HM upregulates the mucin 4 gene expression in human gastric AGS cells, suggesting \u003cem\u003ein vivo\u003c/em\u003e studies to demonstrate the gastroprotective protective action of HM at the biochemical level.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/em\u003e\u003c/strong\u003eCOX enzymes synthesize PGE2 from arachidonic acid throughout the GI tract and mediate both protective and healing effects [3, 5]. In this study,\u0026nbsp;the effect of HM on COX-2 expression in AGS cells was tested using RT-qPCR, Western blot technology and immune-cyto-fluorescence staining. The RT-qPCR data showed that HM increased the expression level of COX-2 in the AGS cells. Similarly, the Western blot analysis showed that the HM augmented COX-2 expression level in a time- and dose-dependent manner. The immunofluorescence staining confirmed these results and revealed the COX-2 expression in the nucleus, plasma membrane compartments, and predominantly localized in the cytoplasm and at the intercellular junctions upon HM treatment. In addition, we tested PGE2 secretion in the supernatant following HM/AGS treatment. Our ELISA results showed that HM increased PGE2 secretion in a time- and dose-dependent manner. As PGE2 is a direct downstream product of COX-2 [48], the\u0026nbsp;ELISA results confirmed the effect of HM in the\u0026nbsp;COX2 pathway\u0026nbsp;activation.\u0026nbsp;To further confirm that HM induced the COX-2 signaling pathway, AGS cells were pre-treated with the NS-398\u0026nbsp;COX-2 pharmacological inhibitor and the results showed a clear reduction in HM-induced COX-2 and PGE2, which indicate and confirm the direct role of HM in \u0026nbsp; activating the COX2/PGE2 signaling pathway.\u003c/p\u003e\n\u003cp\u003eThe COX-2/PGE2 signaling pathway acts in combination with other signaling pathways\u0026nbsp;such as the Ras-MAPK and NF-kB pathway\u0026nbsp;and can be activated by different ligands of the TLRs family [15-17]. The role of TLR4 in activating the COX-2/PGE2 pathway in murine macrophages [49], intestinal epithelial cells [50], auditory cells [51], Barrett\u0026rsquo;s esophagus [52], and in human gastric carcinoma cells\u0026nbsp;[53]\u0026nbsp;has been reported. In the stomach,\u0026nbsp;TLR4 is activated in response to pathogenic invasion, such as \u003cem\u003eHelicabacter Pylori\u0026nbsp;\u003c/em\u003eLPS, leading to the induction of COX-2 expression and PGE2 production\u003cem\u003e\u0026nbsp;in vivo\u0026nbsp;\u003c/em\u003e[54]. The human gastric cell line AGS used in this study was reported to express the TLR4 receptor and the activation of the TLR4 signaling pathway induced by LPS was demonstrated [55]. Previously, we identified HM as a TLR4 ligand and observed a similarity between HM and LPS in TLR4 activation [36].\u0026nbsp;In the present study, the observed increased in COX-2 expression and PGE2 secretion by AGS after HM treatment was anticipated, similar to the HM effect on the TLR4/COX-2/PGE2 pathway activation. To confirm this assumption and provide evidence of the involvement of TLR4 in the observed results, both the TLR4 protein and mRNA expression levels were monitored. The AGS cells were treated in parallel, with HM at 5-10-20\u0026nbsp;mg/mL and LPS at 10\u0026nbsp;mg/mL and Western blot was performed after 72 h incubation. The results showed a clear TLR4 protein upregulation with all the HM concentrations tested or with LPS, as compared to the basal TLR4 expression level detected in untreated cells. Similarly, HM-induced TLR4 mRNA expression was confirmed after 24 h and 72 h incubation indicating the definite role of TLR4 in the HM biological effects. These findings agreed with the reported effects of different TLR4 ligands and COX2/PGE2 activation on gastric mucosa cells both \u003cem\u003ein vitro\u003c/em\u003e and \u003cem\u003ein vivo.\u003c/em\u003e Fukata and colleagues [10] reported that LPS induces TLR4/COX-2 expression in the epithelial cells and in lamina propria macrophages, which results in the upregulation of the mucosal PGE2. They proposed that this increased PGE2 expression might be required for mucosal restitution in response to epithelial injury [10]. Zheng \u003cem\u003eet al\u003c/em\u003e. [56] reported that the administration of hyaluronic acid, another TLR4 ligand, activated the TLR4, induced COX-2 and subsequently PGE2.\u0026nbsp;In addition, Chen \u003cem\u003eet al.\u0026nbsp;\u003c/em\u003e[57] showed that a high-molecular-weight hyaluronic acid protected against induced-gastrointestinal colitis via the activation of TLR4 and COX-2 and PGE2 expression. In these studies, the authors reported the implication of the different TLR4 ligands in the protective mechanism of the gastrointestinal tract, which suggests a similar gastroprotective role of HM.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe effect of HM on IL-6 secretion and production by AGS cells was evaluated using ELISA and Western blot analysis. Our present results showed that HM treatment enhanced IL-6 secretion and production in the supernatant and cell lysates, respectively. We also showed that both the TLR4 inhibitor and the COX-2 inhibitor inhibited HM-induced IL-6 secretion and production. Our results indicated that HM induced IL-6 via the TLR4/COX-2/PGE2 signaling pathway in the AGS gastric cell line, which agreed with literature demonstrating the production of IL-6 via the activation of TLR4/COX-2/PGE2 pathway both\u003cem\u003e\u0026nbsp;in vitro\u0026nbsp;\u003c/em\u003eand \u003cem\u003ein vivo\u003c/em\u003e \u0026nbsp;[58, 59].\u0026nbsp;\u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eIL-6 is a pleiotropic cytokine acting as a pro-inflammatory and anti-inflammatory cytokine, depending on its local concentration as well as the nature of the target cells [60, 61]. In the GI tract, IL-6 is expressed in the gastric, small intestinal and colonic mucosa epithelial cells and has been recognized as a multifaceted cytokine due to its opposing roles of promoting inflammation and malignancy or protecting and repairing effects [62].\u0026nbsp;In the stomach, IL-6 plays an important role in inducing cancer cell invasion and maintaining gastric homeostasis at the same time [17, 63]. Studies using mouse models, provided evidence supporting the beneficial roles of IL-6 signaling in protecting intestinal epithelial cells from apoptosis and\u0026nbsp;maintaining the epithelial barrier integrity [64]. However, many studies related IL-6 overexpression to autoimmune diseases and cancer [65].\u0026nbsp;This controversy in the action of IL-6 has been demonstrated by Gradient \u003cem\u003eet al.\u003c/em\u003e [66] who reported that IL-6 exerts completely opposite actions on neurons, triggering either neuronal survival after injury or causing neuronal degeneration and cell death in disorders such as Alzheimer\u0026apos;s disease.\u0026nbsp;In a previous \u003cem\u003ein vivo\u003c/em\u003e study, we demonstrated that HM protected gastric epithelial cells from alcohol-, indomethacin-, aspirin-, stress-, and combined stress with aspirin-induced gastric ulcers [25]. Using human gastric cancer cell lines,\u0026nbsp;Mej\u0026iacute;as-Luque et al. [20]\u0026nbsp;demonstrated that IL-6 upregulates mucin 4 gene and protein expression levels.\u0026nbsp;In this study, we have shown that HM induced IL-6 in the AGS gastric cell line and increased mucin 4 gene expression levels, which reinforces the HM gastroprotective potential. A blockade of IL-6 production and secretion would demonstrate whether HM upregulates mucin 4 gene expression in an IL-6-dependent manner. In spite of the recent advances indicating that IL-6 has multifaceted activities, and perhaps a beneficial role in protecting the GI tract from injuries, we cannot expect a protective role of IL-6. Additional \u003cem\u003ein vivo\u003c/em\u003e studies are required to elucidate the exact role of HM-induced IL-6 in the stomach.\u003c/p\u003e"},{"header":"Conclusions ","content":"\u003cp\u003eThe current study is the first to demonstrate the stimulatory effect of the HM extracted from \u003cem\u003eNigella sativa\u0026nbsp;\u003c/em\u003e(L.)\u003cem\u003e\u0026nbsp;\u003c/em\u003eblack seed coats on the TLR4/COX-2 pathway in human gastric epithelial cells, resulting in the enhancement of the secretion of PGE2 and IL-6, accompanied by the upregulation of mucin 4 gene expression, three key players contributing to gastroprotection.\u0026nbsp;Additional studies are warranted to investigate HM potential anti-ulcer activities\u003cem\u003e\u0026nbsp;in vivo\u003c/em\u003e.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003ecDNA, complementary deoxyribonucleic acid; COX, cyclooxygenase; DMEM, Dulbecco\u0026rsquo;s modified Eagle medium; DMSO, dimethyl sulfoxide; ELISA, enzyme-linked immunosorbent assay; FBS, fetal bovine serum; FITC, fluorescein isothiocyanate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GI, gastrointestinal; HM, herbal melanin; LPS, lipopolysaccharide; NF-kB, nuclear factor kappa-light-chain-enhancer of activated B-cells; NSAIDs, nonsteroidal anti-inflammatory drugs; PBS, phosphate-buffered saline; PGE2, prostaglandin E2; RNA, ribonucleic acid; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; TLR, toll-like receptor; \u0026nbsp;\u003c/p\u003e"},{"header":"Declarations ","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe datasets generated and analysed during the current study are available in the \u003cem\u003eIn vitro Gastroprotective effects of HM\u003c/em\u003e repository,\u0026nbsp;doi:10.5061/dryad.ht76hdrj7.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that there are no conflicts of interest.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll the carried out experiments were financially supported by King Abdullah International Medical Research Center (KAIMRC) under grant number RC15/080.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026rsquo; contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAE and SMN conceived and conducted the study. YM, GA, MA, HA, NA, AHK and AH performed, generated the data, collected the data, and reviewed the manuscript. AE and SMN interpreted the data, wrote and reviewed the manuscript.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe are grateful to Dr Rizwan Ali from KAIMRC Medical Research Core Facility and Platforms for the use of the confocal scanner lasing microscope and for providing us the confocal images.\u0026nbsp;\u003c/p\u003e"},{"header":"References ","content":"\u003col\u003e\n\u003cli\u003eChelakkot C, Ghim J, Ryu SH. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 2018;50:1-9.\u003c/li\u003e\n\u003cli\u003eWiertsema SP, van Bergenhenegouwen J, Garssen J, Knippels LMJ. The interplay between the gut microbiome and the immune system in the context of infectious diseases throughout life and the role of nutrition in optimizing treatment strategies. Nutrients 2021;13:886.\u003c/li\u003e\n\u003cli\u003eTakeuchi K, Amagase K. Roles of cyclooxygenase, prostaglandin E2 and EP receptors in mucosal protection and ulcer healing in the gastrointestinal tract. Curr Pharm Des. 2018;24:2002-11. \u003c/li\u003e\n\u003cli\u003eSmith WL, Urade Y, Jakobsson PJ. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem Rev. 2011;111:5821-65.\u003c/li\u003e\n\u003cli\u003eGudis K, Sakamoto C. The role of cyclooxygenase in gastric mucosal protection. Dig Dis Sci. 2005;50 Suppl. 1:S16-23.\u003c/li\u003e\n\u003cli\u003eMiller TA. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol. 1983;245:G601-23.\u003c/li\u003e\n\u003cli\u003eRainsford KD. Gastrointestinal adaptation, gastrointestinal injury by NSAIDs. Regulation of eicosanoids and mucosal protection from NSAIDs. In: Rainsford KD, ed. Side eVects of anti-inflammatory drugs\u0026mdash;4. Dordrecht: Kluwer Academic Publishers; 1997:197-205.\u003c/li\u003e\n\u003cli\u003eBjarnason I, Scarpignato C, Holmgren E, Olszewski M, Rainsford KD, Angel Lanas. Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs. Gastroenterology 2018;154:500\u0026ndash;14.\u003c/li\u003e\n\u003cli\u003eBurgue\u0026ntilde;o JF, Abreu MT. Epithelial Toll-like receptors and their role in gut homeostasis and disease. Nat Rev Gastroenterol Hepatol. 2020;17:263-78. \u003c/li\u003e\n\u003cli\u003eFukata M, Chen A, Klepper A, Krishnareddy S, Vamadevan AS, Thomas LS, et al. Cox-2 is regulated by Toll-like Receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology 2006;131:862\u0026ndash;77.\u003c/li\u003e\n\u003cli\u003eTestro AG, Visvanathan K. Toll-like receptors and their role in gastrointestinal disease. J Gastroenterol Hepatol. 2009;24:943-54.\u003c/li\u003e\n\u003cli\u003eLavelle EC, Murphy C, O\u0026rsquo;Neill LAJ, Creagh EM. The role of TLRs, NLRs, and RLRs in mucosal innate immunity and homeostasis. Mucosal Immunol. 2010;3:17-28.\u003c/li\u003e\n\u003cli\u003eRakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009;9:57\u0026ndash;63 \u003c/li\u003e\n\u003cli\u003eSlomiany BL, Slomiany A. Role of LPS-elicited signaling in triggering gastric mucosal inflammatory responses to H. pylori: modulatory effect of ghrelin. Inflammopharmacology 2017;25:415-29.\u003c/li\u003e\n\u003cli\u003eZhang Y, Chen H, Yang L. Toll-like receptor 4 participates in gastric mucosal protection through Cox-2 and PGE2. Dig Liver Dis. 2010;42:472-76.\u003c/li\u003e\n\u003cli\u003eWang P, Zhu F, Konstantopoulos K. Prostaglandin E2 induces interleukin-6 expression in human chondrocytes via cAMP/protein kinase A- and phosphatidylinositol 3-kinase-dependent NF-kB activation. Am J Physiol Cell Physiol. 2010;298:C1445-56. \u003c/li\u003e\n\u003cli\u003eGuo Y, Wang B, Wang T, Gao L, Yang ZJ, Wang FF, et al. Biological characteristics of IL-6 and related intestinal diseases. Int J Biol Sci. 2021;17:204-19.\u003c/li\u003e\n\u003cli\u003eChoy E, Rose-John S. Interleukin-6 as a multifunctional regulator: inflammation, immune response, and fibrosis. J Scleroderma Relat Discord. 2017;2:S1-5.\u003c/li\u003e\n\u003cli\u003eDann SM, Spehlmann ME, Hammond DC, Iimura M, Hase K, Choi LJ, et al. IL-6-dependent mucosal protection prevents establishment of a microbial niche for attaching/effacing lesion-forming enteric bacterial pathogens. J Immunol. 2008;180:6816-26.\u003c/li\u003e\n\u003cli\u003eMej\u0026iacute;as-Luque R, Peir\u0026oacute; S, Vincent A, Van Seuningen I, de Bol\u0026oacute;s C. IL-6 induces MUC4 expression through gp130/STAT3 pathway in gastric cancer cell lines. Biochim Biophys Acta 2008;1783:1728-36.\u003c/li\u003e\n\u003cli\u003eSantana FPR, Pinheiro NM, Mernak MIB, Righetti RF, Martins MA, Lago JHG, et al. Evidence of herbal medicine-derived natural products effects in inflammatory lung diseases. Mediators Inflamm. 2016;2016:2348968. \u003c/li\u003e\n\u003cli\u003eKoshak AE, Yousif NM, Flebich BL, Koshak EA, Heinrich M. Comparative immunomodulatory activity of Nigella sativa L. preparations on proinflammatory mediators: A focus on asthma. Front. Pharmacol. 2018;9:1075.\u003c/li\u003e\n\u003cli\u003eDzobo K, Chiririwa H, Dandara C, Dzobo W. Coronavirus Disease-2019 treatment strategies targeting interleukin-6 signaling and herbal medicine. OMICS 2021;25:13-22.\u003c/li\u003e\n\u003cli\u003eEl-Tahir KEH, Hassib AM, El-Hag H, Pont\u0026eacute;n F, Westermark B, et al. Anti-ulcerogenic effects of Nigella sativa Melanin. 2009; Sudan Patent No. 1683. \u003c/li\u003e\n\u003cli\u003eEl-Obeid A, ELTahir KH, Elhag H, Haseeb AM. Anti-ulcerogenic Effects of Nigella sativa L. Melanin. World J Pharm Res 2016;5:1579-93.\u003c/li\u003e\n\u003cli\u003eKhare CP. Encycopledia of Indian medicinal plants. NewYork: Springer-Verlag Berlin Heidelberg; 2004.\u003c/li\u003e\n\u003cli\u003eYimer EM, Tuem KB, Karim A, Ur-Rehman N, Anwar F. \u003cem\u003eNigella sativa\u003c/em\u003e L. (Black cumin): A promising natural remedy for wide range of illnesses. Evid Based Complement Alternat Med. 2019;2019:1528635.\u003c/li\u003e\n\u003cli\u003eMajdalawieh AF, Fayyad MW. Recent advances on the anti-cancer properties of Nigella sativa, a widely used food additive. J Ayurveda Integr. Med. 2016;7:173-80.\u003c/li\u003e\n\u003cli\u003eMaideen NMP. Antidiabetic activity of \u003cem\u003eNigella Sativa\u003c/em\u003e (Black seeds) and its active constituent (Thymoquinone): A review of human and experimental animal studies. Chonnam Med J. 2021;57:169-175.\u003c/li\u003e\n\u003cli\u003eRafati S, Niakan M, Naseri M. Anti-microbial effect of Nigella sativa seed extract against staphylococcal skin infection. Med J Islam Repub Iran 2014;28:42.\u003c/li\u003e\n\u003cli\u003eAdam GO, Rahman MM, Lee SJ, Kim GB, Kang HS, Kim JS, et al. Hepatoprotective effects of Nigella sativa seed extract against acetaminophen-induced oxidative stress. Asian Pac J Trop Med. 2016;9:221-7\u003c/li\u003e\n\u003cli\u003ePop RM, Sabin O, Suciu Ș, Vesa SC, Socaci SA, Chedea VS, et al. Nigella Sativa\u0026rsquo;s anti-inflammatory and antioxidative effects in experimental inflammation. Antioxidants (Basel) 2020;9:921.\u003c/li\u003e\n\u003cli\u003eHassib, 1998 Hassib, A., 1998. Extraction of melanin from Nigella sativa L. Patent No. 451, Khartoum, Sudan.\u003c/li\u003e\n\u003cli\u003eEl-Obeid A, Al-Harbi S, Al-Jomah N, Hassib A. Herbal melanin modulates tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) production. Phytomedicine 2006;13:324-33. \u003c/li\u003e\n\u003cli\u003eEl-Obeid A, Hassib A, Pont\u0026eacute;n F, Westermark B. Effect of herbal melanin on IL-8: a possible role of Toll-like receptor 4 (TLR4). Biochem Biophys Res Commun. 2006;344:1200-6.\u003c/li\u003e\n\u003cli\u003e\u0026Ouml;berg F, Haseeb A, Ahnfelt M, Pont\u0026eacute;n F, Westermark B, El-Obeid A. Herbal melanin activates TLR4/NF-kappaB signaling pathway. Phytomedicine 2009;16:477-84.\u003c/li\u003e\n\u003cli\u003eEl-Obeid A, Yahya WB, Almuzzaini B, Al Tuwaijri A, Najdi M, Hassib A, Matou-Nasri S. Herbal melanin induces interleukin-1b secretion and production by human THP-1 monocytes via Toll-like receptor 2 and p38 MAPK activation. Exp Ther Med. 2021;22:1081.\u003c/li\u003e\n\u003cli\u003eEl-Obeid A, Alajmi H, Harbi M, Yahya WB, Al-Eidi H, Alaujan M, et al. Distinct anti-proliferative effects of herbal melanin on human acute monocytic leukemia THP-1 cells and embryonic kidney HEK293 cells. BMC Complement Med Ther. 2020;20:154.\u003c/li\u003e\n\u003cli\u003eAl-Obeed O, El-Obeid AS, Matou-Nasri S, Vaali-Mohammed MA, AlHaidan Y, Elwatidy M, et al. Herbal melanin inhibits colorectal cancer cell proliferation by altering redox balance, inducing apoptosis, and modulating MAPK signaling. Cancer Cell Int. 2020;20:126. \u003c/li\u003e\n\u003cli\u003eMimura T, Maeda K, Terada T, Oda Y, Morishita K, Aonuma S. Studies on biological activities of melanin from marine animals. III. Inhibitory effect of SM II (low molecular weight melanoprotein from squid) on phenylbutazone-induced ulceration in gastric mucosa in rats, and its mechanism of action. Chem Pharm Bull (Tokyo). 1985;33:2052-60.\u003c/li\u003e\n\u003cli\u003eElObeid AS, Kamal-Eldin A, Abdelhalim MAK, Haseeb AM. Pharmacological properties of melanin and its function in health. Basic Clin Pharmacol Toxicol. 2017;120:515-22.\u003c/li\u003e\n\u003cli\u003eKonturek PC, Brzozowski T, Meixner H, Ptak A, Hahn EG, Konturek SJ. Central and peripheral neural aspects of gastroprotective and ulcer healing effects of lipopolysaccharides. J Physiol Pharmacol. 2001;52:611-23.\u003c/li\u003e\n\u003cli\u003eRameshbabu S, Messaoudi SA, Alehaideb ZI, Ali MS, Venktraman A, AlajmiH, et al. \u003cem\u003eAnastatica hierochuntica\u003c/em\u003e (L.) methanolic and aqueous extracts exert antiproliferative effects through the induction of apoptosis in MCF-7 breast cancer cells. Saudi Pharm J 2020;28:985-993.\u003c/li\u003e\n\u003cli\u003eRyan SW. Management of dyspepsia and peptic ulcer disease. Altern Ther Health Med. 2005;11:26-29.\u003c/li\u003e\n\u003cli\u003eZayachkivska OS, Konturek SJ, Drozdowicz D, Konturek PC, Brzozowski T, Ghegotsky MR. Gastroprotective effects of flavonoids in plant extracts. J Physiol Pharmacol. 2005;56:219-31.\u003c/li\u003e\n\u003cli\u003eEl-Dakhakhny M., Mady N.I., Halim M.A. Nigella sativa L. oil protects against induced hepatotoxicity and improves serum lipid profile in rats. Arzneimittelforschung 2000;50:832-6.\u003c/li\u003e\n\u003cli\u003eKanter M, Demir H, Karakaya C, Ozbek H. Gastroprotective activity of Nigella sativa L. oil and its constituent, thymoquinone against acute alcohol-induced gastric mucosal injury in rats. World J Gastroenterol. 2005;11:6662-6.\u003c/li\u003e\n\u003cli\u003eGiuliano F, Warner TD. Origins of prostaglandin E2: involvements of cyclooxygenase (COX)-1 and COX-2 in human and rat systems. J Pharmacol Exp Ther. 2002;303:1001-6.\u003c/li\u003e\n\u003cli\u003eZhang Y, Igwe OJ. Lipopolysaccharide (LPS)-mediated priming of toll-like receptor 4 enhances oxidant-induced prostaglandin E\u003csub\u003e2\u003c/sub\u003e biosynthesis in primary murine macrophages. Int Immunopharmacol. 2018;54:226-37.\u003c/li\u003e\n\u003cli\u003eFukata M, Chen A, Klepper A, Krishnareddy S, Vamadevan AS, Thomas LS, et al. Cox-2 is regulated by toll-like receptor-4 (TLR4) signaling and is important for proliferation and apoptosis in response to intestinal mucosal injury. Gastrointestinal 2006;131:862-77.\u003c/li\u003e\n\u003cli\u003eTanigawa T, Odkhuu E, Morikawa A, Hayashi K, Sato T, Shibata R, et al. Immunological role of prostaglandin E2 production in mouse auditory cells in response to LPS. Innate Immun. 2014;20:639-46.\u003c/li\u003e\n\u003cli\u003eVerbeek RE, Siersema PD, Ten Kate FJ, Fluiter K, Souza RF, Vleggaar FP, et al. Toll-like receptor 4 activation in Barrett\u0026rsquo;s esophagus results in a strong increase in COX-2 expression. J Gastroenterol. 2014;49:1121-34.\u003c/li\u003e\n\u003cli\u003eSchmausser B, Andrulis M, Endrich S, M\u0026uuml;ller-Hermelink HK, Eck M. Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol.2005;295:179-185.\u003c/li\u003e\n\u003cli\u003eScott T, Owens MD. Thrombocytes respond to lipopolysaccharide through Toll-like receptor-4, and MAP kinase and NF-kappaB pathways leading to expression of interleukin-6 and cyclooxygenase-2 with production of prostaglandin E\u003csub\u003e2\u003c/sub\u003e. Mol Immunol. 2008;45:1001-8.\u003c/li\u003e\n\u003cli\u003eSu B, Ceponis PJM, Lebel S, Huynh H, Sherman PM. \u003cem\u003eHelicobacter pylori\u003c/em\u003e activates Toll-like receptor 4 expression in gastrointestinal epithelial cells. Infect Immun. 2003;71:3496-502.\u003c/li\u003e\n\u003cli\u003eZheng L, Riehl T, Stenson WF. Regulation of colonic epithelial repair in mice by Toll-like receptors and hyaluronic acid. Gastroenterology 2009;137:2041-51.\u003c/li\u003e\n\u003cli\u003eChen H, Mahaseth M, Zhang Y. Hyaluronic acid as a rescue therapy for trinitrobenzene sulfonic acid-induced colitis through Cox-2 and PGE\u003csub\u003e2\u003c/sub\u003e in a Toll-like receptor 4-dependent way. J Zhejiang Univ Sci B. 2011;12:712-9.\u003c/li\u003e\n\u003cli\u003eLin CC, Lee IT, Yang YL, Lee CW, Kou YR, Yang CM. Induction of COX-2/PGE(2)/IL-6 is crucial for cigarette smoke extract-induced airway inflammation: Role of TLR4-dependent NADPH oxidase activation. Free Radic Biol Med. 2010;48:240-54.\u003c/li\u003e\n\u003cli\u003eRaveendran VV, Tan X, Sweeney ME, Levant B, Slusser J, Stechschulte DJ, et al. Lipopolysaccharide induces H1 receptor expression and enhances histamine responsiveness in human coronary artery endothelial cells. Immunology 2011;132:578-88.\u003c/li\u003e\n\u003cli\u003eAlonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias, G, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 1998;187:461-8.\u003c/li\u003e\n\u003cli\u003eYasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, Aki D, et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol. 2003;4:551-6.\u003c/li\u003e\n\u003cli\u003eKuhn KA, Manieri NA, Liu TC, Stappenbeck TS. IL-6 stimulates intestinal epithelial proliferation and repair after injury. PLoS One 2014;9:e114195.\u003c/li\u003e\n\u003cli\u003eLin MT, Lin BR, Chang CC, Chu CY, Su HJ, Chen ST, et al. IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. Int J Cancer 2007;120:2600-8.\u003c/li\u003e\n\u003cli\u003eKuhn KA, Schulz HM, Regner EH, Severs EL, Hendrickson JD, Mehta G, et al. Bacteroidales recruit IL-6-producing intraepithelial lymphocytes in the colon to promote barrier integrity. Mucosal Immunol. 2018;11:357-68.\u003c/li\u003e\n\u003cli\u003eKumari N, Dwarakanath BS, Asmita D, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016;37:11553-72.\u003c/li\u003e\n\u003cli\u003eGadient RA, Otten UH. Interleukin-6 (IL-6)-- A molecule with both beneficial and destructive potentials. Prog Neurobiol. 1997;52:379-90.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bmc-complementary-medicine-and-therapies","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bcam","sideBox":"Learn more about [BMC Complementary Medicine and Therapies](https://bmccomplementmedtherapies.biomedcentral.com/)","snPcode":"","submissionUrl":"","title":"BMC Complementary Medicine and Therapies","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Herbal melanin, gastrointestinal, gastroprotection, TLR, COX-2, IL-6","lastPublishedDoi":"10.21203/rs.3.rs-1597711/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-1597711/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"We reported a gastric anti-ulcerogenic effect of the Nigella sativa (L.)-derived herbal melanin (HM) in rat models. However, the molecular mechanisms underlying the HM gastroprotective effect remain unknown. Cyclooxygenase-2 (COX-2)-catalyzed prostaglandin E2 (PGE2) and toll-like receptor 4 (TLR4)-mediated interleukin-6 (IL-6) production and secretion play major roles in gastric mucosal protection. In the current study, we investigated the effect of HM on TLR4, COX-2, and on gastroprotective markers PGE2 and IL-6 expression, using the human gastric cancer cell line AGS. Bacterial lipopolysaccharide (LPS), a well-known inducer of gastroprotective marker expression, was used as a positive control. After cell exposure to HM and LPS, the cell lysates and supernatants were tested for COX-2, PGE2, and IL-6 production and secretion using Western blot technology and an enzyme-linked immunosorbent assay (ELISA), respectively. Immuno-cyto-fluorescence staining was applied for COX-2 cellular localization and RT-qPCR for monitoring the gene expression levels of TLR4, COX-2, and mucin 4, an important gastroprotective glycoprotein. In this study, we showed that HM upregulated its main receptor TLR4 gene and protein expression. HM increased, in a dose- and time-dependent manner, the secretion of PGE2 and the expression of COX-2 mRNA and protein, which was detected in the nucleus, cytoplasm and predominantly at the intercellular junctions. In addition, HM enhanced IL-6 production and secretion, and upregulated the mucin 4 gene expression, the hallmarks of gastroprotection. To check whether HM-induced PGE2 and IL-6 through TLR4 signaling and COX-2 generated, AGS cells were pre-treated with a TLR4 signaling inhibitor TAK242 and the COX-2 inhibitor NS-398. An inhibition of HM-induced COX-2, PGE2 and IL-6 production was observed in TAK242 and NS-398-pre-treated AGS cells, confirming the role of TLR4 signaling and of COX-2 generated in the possible HM gastroprotective effects. In conclusion, our results showed that HM enhances TLR4/COX-2-mediated secretion of gastroprotective markers PGE2 and IL-6, and upregulates mucin 4 gene expression in the human gastric cancer cell line AGS.","manuscriptTitle":"Herbal melanin modulates PGE2 and IL-6 gastroprotective markers through COX-2 and TLR4 signaling in the gastric cancer cell line AGS","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2022-05-13 15:47:54","doi":"10.21203/rs.3.rs-1597711/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Major revision","date":"2022-11-22T06:08:22+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2022-11-18T23:48:19+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"75a9f525-3b8f-4391-ac5b-7c23b4496dbe","date":"2022-11-10T19:55:43+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"9a5838c5-a598-4582-a8e4-3f810bbe911d","date":"2022-08-16T06:33:41+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2022-07-25T08:18:44+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"1d7204cb-134f-4e6c-b072-64d3113ec803","date":"2022-07-15T00:54:28+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2022-05-15T05:20:44+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2022-05-10T05:14:15+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2022-05-09T17:53:47+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2022-05-09T06:01:32+00:00","index":"","fulltext":""},{"type":"submitted","content":"BMC Complementary Medicine and Therapies","date":"2022-04-26T14:35:22+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-complementary-medicine-and-therapies","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bcam","sideBox":"Learn more about [BMC Complementary Medicine and Therapies](https://bmccomplementmedtherapies.biomedcentral.com/)","snPcode":"","submissionUrl":"","title":"BMC Complementary Medicine and Therapies","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"1c9e3450-5d77-498c-b89a-8d6162ebfe8e","owner":[],"postedDate":"May 13th, 2022","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[],"tags":[],"updatedAt":"2023-08-11T13:59:20+00:00","versionOfRecord":[],"versionCreatedAt":"2022-05-13 15:47:54","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-1597711","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-1597711","identity":"rs-1597711","version":["v1"]},"buildId":"-HB7Z8yhvgn0wM9Nzuekk","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}